Paul Ridker

Q: What Schools Are Affiliated With Paul Ridker

Paul Ridker is affiliated with the following schools: Massachusetts General Hospital, Karolinska Institute, University of Cambridge, Harvard University, Sahlgrenska Academy, University of Oslo, Brown University, Yale University, McMaster University

Paul Ridker's AcademicInfluence.com Rankings

Paul Ridker

Philosophy

#1006

World Rank

#1916

Historical Rank

#429

USA Rank

Logic

#115

World Rank

#285

Historical Rank

#51

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Paul Ridker Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Paul M. Ridker is a cardiovascular epidemiologist and biomedical researcher. He is currently the Eugene Braunwald Professor of Medicine at Harvard University and Brigham and Women's Hospital, where he directs the Center for Cardiovascular Disease Prevention. Ridker also holds an appointment as Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health.

(See a Problem?)

Paul Ridker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. (2000) (6050)
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. (1997) (5677)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (2017) (5238)
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. (2008) (4914)
Inflammation and Atherosclerosis (2002) (4911)
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. (2001) (4267)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Genetic studies of body mass index yield new insights for obesity biology (2015) (3549)
Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids (2010) (3485)
Progress and challenges in translating the biology of atherosclerosis (2011) (3271)
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. (2003) (2963)
Clinical application of C-reactive protein for cardiovascular disease detection and prevention. (2003) (2486)
Discovery and Refinement of Loci Associated with Lipid Levels (2013) (2475)
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. (2000) (2460)
C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women (2003) (2421)
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. (1996) (2393)
C-reactive protein levels and outcomes after statin therapy. (2005) (2243)
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index (2010) (2011)
Hundreds of variants clustered in genomic loci and biological pathways affect human height (2010) (1961)
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women (2005) (1947)
Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk (2011) (1928)
Inflammation in atherosclerosis: from pathophysiology to practice. (2009) (1838)
Defining the role of common variation in the genomic and biological architecture of adult human height (2014) (1805)
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. (1998) (1788)
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction (1995) (1755)
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. (2007) (1720)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. (2001) (1665)
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. (2002) (1571)
A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease (2015) (1567)
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. (2007) (1547)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. (1998) (1476)
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein (1999) (1460)
Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. (2001) (1405)
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. (2001) (1398)
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men (1998) (1290)
Interpretation of the evidence for the efficacy and safety of statin therapy (2016) (1290)
Inflammation as a Cardiovascular Risk Factor (2004) (1277)
New genetic loci link adipose and insulin biology to body fat distribution (2014) (1227)
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. (2001) (1202)
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. (2003) (1200)
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. (2002) (1189)
Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index (2010) (1179)
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. (1995) (1127)
Efficient Bayesian mixed model analysis increases association power in large cohorts (2014) (1114)
Genome-wide meta-analyses identify multiple loci associated with smoking behavior (2010) (1107)
C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. (1998) (1076)
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. (2004) (1070)
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture (2012) (1045)
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. (1998) (1015)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (2009) (989)
C-reactive protein and the risk of developing hypertension. (2003) (970)
Physical Activity and Reduced Risk of Cardiovascular Events: Potential Mediating Mechanisms (2007) (961)
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. (2000) (958)
C-reactive protein, fibrinogen, and cardiovascular disease prediction. (2012) (952)
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. (2007) (926)
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution (2010) (897)
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. (2000) (897)
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. (2005) (861)
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. (2016) (847)
C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men (2008) (839)
Novel clinical markers of vascular wall inflammation. (2001) (822)
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms (2005) (820)
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin (2008) (814)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials (2009) (781)
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). (2011) (779)
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. (2005) (769)
Common variants associated with plasma triglycerides and risk for coronary artery disease (2013) (767)
New loci associated with kidney function and chronic kidney disease (2010) (754)
Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial (2005) (746)
Inflammatory bio‐markers and cardiovascular risk prediction (2002) (735)
Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries (2018) (735)
Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. (2002) (734)
Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events (2019) (733)
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial (2012) (729)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (2017) (713)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (2017) (713)
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. (2009) (695)
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? (2004) (686)
Blood Pressure and Inflammation in Apparently Healthy Men (2001) (685)
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) (681)
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations (2012) (678)
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. (1999) (668)
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits (2018) (659)
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies (2012) (646)
Endogenous tissue-type plasminogen activator and risk of myocardial infarction (1993) (629)
Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. (1997) (626)
Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. (2004) (601)
C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. (2007) (595)
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. (1999) (593)
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. (2011) (589)
Population analysis of large copy number variants and hotspots of human genetic disease. (2009) (589)
Multiple loci associated with indices of renal function and chronic kidney disease (2009) (583)
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (2018) (578)
Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. (2002) (576)
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture (2013) (568)
Soluble P-Selectin and the Risk of Future Cardiovascular Events (2001) (564)
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. (2001) (563)
From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. (2016) (560)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials (2015) (559)
Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death (2002) (559)
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial (2017) (558)
Meta-analysis identifies six new susceptibility loci for atrial fibrillation (2012) (535)
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. (2012) (532)
The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study (2015) (532)
The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women (2006) (529)
A prospective study of lipoprotein(a) and the risk of myocardial infarction. (1993) (515)
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials (2015) (515)
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. (2014) (513)
Parent-of-origin specific allelic associations among 106 genomic loci for age at menarche (2014) (511)
Rare and low-frequency coding variants alter human adult height (2016) (511)
Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children (2011) (508)
Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores (2004) (502)
Soluble CD40L and Cardiovascular Risk in Women (2001) (491)
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events (2003) (490)
Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients (2017) (488)
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. (1999) (487)
Hormone replacement therapy and increased plasma concentration of C-reactive protein. (1999) (484)
Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures (2009) (484)
Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. (2005) (483)
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies (2010) (477)
Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels (2011) (476)
Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia (2001) (469)
Anti-inflammatory therapies for cardiovascular disease. (2014) (467)
Statins: new American guidelines for prevention of cardiovascular disease (2013) (466)
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. (2003) (463)
Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women (2002) (463)
Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. (2004) (458)
Lipid-related markers and cardiovascular disease prediction. (2012) (457)
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. (2011) (453)
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women (2009) (443)
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. (2001) (442)
C-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke (2003) (438)
The primary prevention of myocardial infarction. (1992) (433)
Novel inflammatory markers of coronary risk: theory versus practice. (1999) (433)
Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. (2006) (432)
Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function (1993) (430)
Exome-wide association study of plasma lipids in >300,000 individuals (2017) (428)
Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk (2017) (428)
Multi-ethnic genome-wide association study for atrial fibrillation (2018) (425)
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure (2011) (424)
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions (2019) (423)
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. (2001) (418)
Erratum: Detection and interpretation of shared genetic influences on 42 human traits (2016) (417)
Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women (2002) (415)
High-sensitivity C-reactive protein: clinical importance. (2004) (411)
Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) (2004) (410)
FTO genotype is associated with phenotypic variability of body mass index (2012) (407)
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis (2009) (407)
A guiding map for inflammation (2017) (402)
Whole‐genome sequencing identifies EN1 as a determinant of bone density and fracture (2015) (399)
Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events (2008) (399)
The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). (2010) (391)
Relation between markers of systemic vascular inflammation and smoking in women. (2002) (390)
Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function (2016) (388)
C-reactive protein and other inflammatory risk markers in acute coronary syndromes. (2003) (380)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Association between a literature-based genetic risk score and cardiovascular events in women. (2010) (371)
Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show Sexual Dimorphism in Genetic Loci for Anthropometric Traits (2013) (365)
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. (2013) (365)
Genome-wide association studies identify novel loci associated with age at menarche and age at natural menopause (2009) (363)
Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks? (1999) (361)
Genome-wide association study reveals three susceptibility loci for common migraine in the general population (2011) (361)
Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular Events (2003) (360)
Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk (2017) (359)
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. (1999) (357)
PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis (1997) (351)
Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease (2007) (347)
The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals (2016) (347)
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. (2008) (346)
Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial (2012) (346)
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. (2006) (346)
Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis (2009) (345)
Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events (2006) (341)
Alcohol Consumption and Plasma Concentration of C-Reactive Protein (2003) (336)
Genome-wide meta-analysis identifies new susceptibility loci for migraine (2013) (336)
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. (2004) (333)
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. (2020) (331)
Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. (2018) (330)
Prospective study of endogenous tissue plasminogen activator and risk of stroke (1994) (325)
Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors (2010) (323)
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) (2018) (320)
Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆ (2001) (317)
Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. (1990) (309)
Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis (2017) (308)
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure (2019) (308)
Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair (2015) (308)
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score (2003) (306)
Novel Association of ABO Histo-Blood Group Antigen with Soluble ICAM-1: Results of a Genome-Wide Association Study of 6,578 Women (2008) (303)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) (2013) (303)
Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. (2006) (296)
Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes (2017) (294)
Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. (1997) (292)
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. (2001) (291)
G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. (1999) (290)
Inactivating mutations in NPC1L1 and protection from coronary heart disease. (2014) (289)
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure (2020) (288)
Factor V Leiden Mutation and the Risks for Thromboembolic Disease: A Clinical Perspective (1997) (288)
C-reactive protein, inflammation, and coronary risk. (2000) (287)
Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. (2007) (284)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study (2017) (283)
High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. (2004) (283)
Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) (2009) (282)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials (2018) (281)
Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. (2005) (280)
Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. (1998) (280)
Sugar-sweetened beverages and genetic risk of obesity. (2012) (278)
Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3 (2009) (275)
Relationship of total and abdominal adiposity with CRP and IL-6 in women. (2003) (275)
Antioxidant Vitamins C and E Improve Endothelial Function in Children With Hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial (2003) (273)
Homocysteine and risk of cardiovascular disease among postmenopausal women. (1999) (270)
Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. (1995) (269)
Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. (1994) (269)
Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. (1994) (267)
High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. (2003) (264)
The American Journal of Cardiology and Journal of Periodontology editors' consensus: periodontitis and atherosclerotic cardiovascular disease. (2009) (264)
Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab (2017) (262)
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. (2004) (260)
Inflammation, C-reactive protein, and atherothrombosis. (2008) (259)
Impact of Traditional and Novel Risk Factors on the Relationship Between Socioeconomic Status and Incident Cardiovascular Events (2006) (259)
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. (2005) (256)
Risk Factors for Progression of Peripheral Arterial Disease in Large and Small Vessels (2006) (253)
C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). (2004) (252)
A catalog of genetic loci associated with kidney function from analyses of a million individuals (2019) (252)
Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction (2004) (251)
Genome-wide analysis identifies 12 loci influencing human reproductive behavior (2016) (250)
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals (2018) (249)
Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative (2012) (247)
Sex Hormone Levels and Risk of Cardiovascular Events in Postmenopausal Women (2003) (246)
Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial (2012) (244)
Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study (2002) (244)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study (2018) (244)
Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation (2017) (243)
Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. (2001) (243)
Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies (2014) (241)
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? (2002) (241)
A Test in Context: High-Sensitivity C-Reactive Protein. (2016) (240)
Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. (1999) (240)
Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations (2010) (238)
A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. (2001) (234)
Association of Common CRP Gene Variants with CRP Levels and Cardiovascular Events (2005) (233)
Soluble Intercellular Adhesion Molecule-1, Soluble Vascular Adhesion Molecule-1, and the Development of Symptomatic Peripheral Arterial Disease in Men (2002) (231)
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. (2001) (229)
Height and Incidence of Cardiovascular Disease in Male Physicians (1993) (229)
A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians (2014) (228)
Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial (2010) (227)
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. (2009) (226)
High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy (2013) (225)
Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption (2014) (224)
Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. (1997) (224)
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. (1991) (224)
Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. (2002) (221)
Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. (2018) (221)
Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women (2007) (221)
LDL cholesterol: controversies and future therapeutic directions (2014) (220)
Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. (2012) (220)
Lipid levels and the risk of ischemic stroke in women (2007) (218)
Statin Use and Leg Functioning in Patients With and Without Lower-Extremity Peripheral Arterial Disease (2003) (216)
Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. (2015) (216)
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? (2006) (216)
C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women (2003) (216)
C-reactive protein comes of age (2005) (215)
Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci (2016) (214)
Factor V Leiden Mutation as a Risk Factor for Recurrent Pregnancy Loss (1998) (214)
Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. (2006) (213)
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism☆ (2003) (212)
Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genomewide Analysis Among 18 245 Initially Healthy Women From the Women’s Genome Health Study (2009) (212)
Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism (2017) (209)
Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). (2011) (209)
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. (1997) (209)
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. (2018) (209)
Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. (2010) (208)
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. (2007) (208)
COVID-19 – A vascular disease (2020) (207)
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins (2014) (207)
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. (1992) (207)
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy (2013) (206)
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. (2010) (202)
Dietary glycemic index, dietary glycemic load, blood lipids, and C-reactive protein. (2008) (200)
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. (2000) (200)
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. (2021) (200)
Genetic evidence of assortative mating in humans (2017) (199)
KLB is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference (2016) (198)
Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. (2008) (197)
C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. (2009) (197)
Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice (2006) (195)
Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. (2001) (195)
Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium (2016) (193)
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. (2008) (193)
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity (2017) (193)
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial (2010) (191)
Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open angle glaucoma (2015) (190)
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. (2007) (189)
Glycated hemoglobin measurement and prediction of cardiovascular disease. (2014) (189)
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. (1997) (187)
Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. (1998) (186)
Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility (2015) (185)
Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study (2011) (185)
On the Use of Variance per Genotype as a Tool to Identify Quantitative Trait Interaction Effects: A Report from the Women's Genome Health Study (2010) (183)
Effect of physical activity on serum C-reactive protein. (2004) (183)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. (2012) (182)
Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. (2004) (181)
Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function (2012) (180)
Corrigendum: 1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function (2017) (180)
Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. (1985) (179)
Gene × Physical Activity Interactions in Obesity: Combined Analysis of 111,421 Individuals of European Ancestry (2013) (178)
Association of Hypertension Drug Target Genes With Blood Pressure and Hypertension in 86 588 Individuals (2011) (178)
Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. (2016) (177)
Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. (2013) (176)
Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events (2014) (176)
COMFREY HERB TEA AND HEPATIC VENO-OCCLUSIVE DISEASE (1989) (175)
Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis (2013) (174)
A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events (2014) (171)
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. (2009) (170)
AJC editor's consensus: psoriasis and coronary artery disease. (2008) (169)
Discrimination in absorption or transport of beta-carotene isomers after oral supplementation with either all-trans- or 9-cis-beta-carotene. (1995) (165)
Lipoprotein(a) and risk of type 2 diabetes. (2010) (164)
Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. (2000) (163)
A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. (1999) (163)
Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) (2017) (163)
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. (2009) (163)
Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) (2010) (163)
Novel locus including FGF21 is associated with dietary macronutrient intake. (2013) (161)
Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. (2014) (161)
Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women (2010) (161)
Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. (2013) (160)
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. (2016) (159)
C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. (2003) (159)
Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT–TIMI 22 (2009) (159)
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? (1998) (158)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Genome-wide physical activity interactions in adiposity ― A meta-analysis of 200,452 adults (2017) (153)
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis (2019) (153)
The Trans-Ancestral Genomic Architecture of Glycemic Traits (2020) (151)
FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals. (2014) (151)
Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. (1999) (150)
Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). (2010) (150)
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial (2018) (150)
On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. (2002) (150)
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways (2012) (150)
Biomarkers of Inflammation and Thrombosis as Predictors of Near-Term Mortality in Patients with Peripheral Arterial Disease: A Cohort Study (2008) (149)
Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits (2017) (149)
Meta-analyses identify 13 novel loci associated with age at menopause and highlights DNA repair and immune pathways (2011) (149)
Tree and spline based association analysis of gene–gene interaction models for ischemic stroke (2004) (149)
Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC Trial (2006) (149)
Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels (2016) (147)
Role of inflammatory biomarkers in prediction of coronary heart disease (2001) (146)
Physical and neurobehavioral determinants of reproductive onset and success (2016) (146)
Comparison of Interleukin-6 and C-Reactive Protein for the Risk of Developing Hypertension in Women (2007) (146)
Loci influencing blood pressure identified using a cardiovascular gene-centric array. (2013) (145)
Circulating Levels of Endothelial Adhesion Molecules and Risk of Diabetes in an Ethnically Diverse Cohort of Women (2007) (144)
Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. (2000) (144)
Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. (2007) (144)
Directional dominance on stature and cognition in diverse human populations (2015) (144)
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. (2018) (144)
Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. (2005) (143)
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021) (143)
Effect of marathon running on inflammatory and hemostatic markers. (2001) (142)
An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene Interactions on risk of myocardial infarction: The importance of model validation (2004) (141)
Genetic Loci Associated With Plasma Concentration of Low-Density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, Triglycerides, Apolipoprotein A1, and Apolipoprotein B Among 6382 White Women in Genome-Wide Analysis With Replication (2008) (141)
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. (2012) (140)
Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score (2013) (139)
A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. (2010) (138)
Plasma concentration of lipoprotein(a) and the risk of future stroke. (1995) (137)
Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. (2012) (135)
Age-Specific Incidence Rates of Venous Thromboembolism among Heterozygous Carriers of Factor V Leiden Mutation (1997) (135)
Baseline IgG Antibody Titers to Chlamydia pneumoniae, Helicobacter pylori, Herpes Simplex Virus, and Cytomegalovirus and the Risk for Cardiovascular Disease in Women (1999) (134)
Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease (2013) (133)
C-Reactive Protein Levels Are Not Associated with Increased Risk for Colorectal Cancer in Women (2005) (133)
The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. (2006) (133)
Estimating treatment effects for individual patients based on the results of randomised clinical trials (2011) (132)
Discordance between Meta-analyses and Large-Scale Randomized, Controlled Trials: Examples from the Management of Acute Myocardial Infarction (1995) (131)
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. (2007) (130)
Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells (2019) (129)
A large-scale candidate gene association study of age at menarche and age at natural menopause (2010) (129)
Symptomatic Peripheral Arterial Disease in Women: Nontraditional Biomarkers of Elevated Risk (2008) (129)
Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. (1998) (129)
The power of genetic diversity in genome-wide association studies of lipids (2021) (129)
Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women’s Health Study (2007) (127)
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. (2005) (127)
The JUPITER Trial: Results, Controversies, and Implications for Prevention (2009) (126)
GWAS for executive function and processing speed suggests involvement of the CADM2 gene (2016) (125)
Targeting cardiovascular inflammation: next steps in clinical translation. (2020) (124)
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. (2021) (124)
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. (2020) (124)
Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease (2015) (124)
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials (2015) (123)
Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. (2004) (122)
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. (1995) (122)
Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. (1999) (121)
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy (2018) (121)
Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney (2017) (121)
Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies (2016) (118)
Novel genetic markers improve measures of atrial fibrillation risk prediction (2013) (118)
Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus: The Women's Health Study (2011) (118)
Pleiotropic genes for metabolic syndrome and inflammation. (2014) (118)
Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. (2003) (117)
Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity (2017) (117)
Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. (2009) (116)
Supplementation with β-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation (1995) (116)
Novel Associations of CPS1, MUT, NOX4, and DPEP1 With Plasma Homocysteine in a Healthy Population: A Genome-Wide Evaluation of 13 974 Participants in the Women’s Genome Health Study (2009) (115)
Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women (2018) (115)
C-reactive protein, inflammation, and coronary risk. (2003) (114)
Genome-wide association study of kidney function decline in individuals of European descent (2014) (114)
Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction (2003) (113)
Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness (2017) (113)
C-reactive protein and risk of cardiovascular disease: Evidence and clinical application (2003) (113)
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease (2021) (112)
Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. (2003) (112)
Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial (2005) (112)
An assessment by the Statin Diabetes Safety Task Force: 2014 update. (2014) (112)
Migraine and Biomarkers of Cardiovascular Disease in Women (2008) (110)
Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia. (2014) (110)
Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). (2005) (110)
Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? (2008) (109)
Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. (2007) (109)
Genetic Variants of Arachidonate 5-Lipoxygenase–Activating Protein, and Risk of Incident Myocardial Infarction and Ischemic Stroke: A Nested Case-Control Approach (2006) (109)
Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. (1999) (108)
Genomic and Transcriptomic Association Studies Identify 16 Novel Susceptibility Loci for Venous Thromboembolism. (2019) (107)
Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease (2016) (106)
Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. (2018) (106)
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial (2019) (106)
A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (2013) (106)
Lipid biomarkers and long-term risk of cancer in the Women's Health Study. (2016) (105)
Interrelationships between inflammation, C-reactive protein, and insulin resistance. (2006) (105)
A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. (2008) (105)
Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women. (2006) (104)
High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. (2012) (104)
Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? (2004) (104)
Genome-wide analysis of dental caries and periodontitis combining clinical and self-reported data (2019) (104)
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution (2011) (104)
How Common Is Residual Inflammatory Risk? (2017) (103)
Hemoglobin A1c level and future cardiovascular events among women. (2004) (103)
Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. (2009) (102)
Are statins anti-inflammatory? (2000) (102)
Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. (2004) (101)
The gene encoding atrial natriuretic peptide and the risk of human stroke. (1999) (101)
A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. (2018) (100)
A prospective study of plasma lipid levels and hypertension in women. (2005) (100)
D-Dimer, Inflammatory Markers, and Lower Extremity Functioning in Patients With and Without Peripheral Arterial Disease (2003) (100)
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. (2003) (99)
A genome-wide association study of early menopause and the combined impact of identified variants (2013) (99)
C-reactive protein, inflammation, and cardiovascular disease: clinical update. (2005) (99)
Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) Study Design (2010) (99)
Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial (2008) (98)
GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes (2018) (98)
A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans (2010) (98)
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. (2020) (98)
Novel Association of HK1 with Glycated Hemoglobin in a Non-Diabetic Population: A Genome-Wide Evaluation of 14,618 Participants in the Women's Genome Health Study (2008) (98)
Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine (2015) (98)
Effects of Interleukin-1 Inhibition With Canakinumab on Hemoglobin A 1 c , Lipids , C-Reactive Protein , Interleukin-6 , and Fibrinogen A Phase IIb Randomized , Placebo-Controlled Trial (2012) (97)
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. (1993) (97)
Lifestyle Interaction With Fat Mass and Obesity-Associated (FTO) Genotype and Risk of Obesity in Apparently Healthy U.S. Women (2011) (96)
Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol (2017) (96)
Cardiovascular risks associated with incident and prevalent periodontal disease. (2015) (96)
Socioeconomic Status and Incident Type 2 Diabetes Mellitus: Data from the Women's Health Study (2011) (96)
The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. (2021) (96)
C-reactive protein and risk of breast cancer. (2007) (95)
1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function (2017) (95)
Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids (2019) (93)
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease (2019) (92)
The effect of statin therapy on lipoprotein associated phospholipase A2 levels. (2005) (92)
Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. (2002) (91)
Soluble CD40 Ligand Levels Indicate Lipid Accumulation in Carotid Atheroma: An In Vivo Study With High-Resolution MRI (2003) (91)
Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. (2017) (90)
A Prospective Study of Helicobacter pylori Seropositivity and the Risk for Future Myocardial Infarction among Socioeconomically Similar U.S. Men (2001) (89)
Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. (2008) (89)
G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. (2001) (89)
Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus (2015) (89)
A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer. (2013) (88)
Fibrinolytic and Inflammatory Markers for Arterial Occlusion: The Evolving Epidemiology of Thrombosis and Hemostasis (1997) (88)
Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. (2006) (88)
Novel Loci, Including Those Related to Crohn Disease, Psoriasis, and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17 686 Women: The Women's Genome Health Study (2009) (88)
Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates? (2012) (88)
Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 Loci (2011) (87)
Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. (2009) (86)
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. (2002) (86)
Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. (2003) (86)
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. (1999) (86)
A Common Variant at 9p21 Is Associated With Sudden and Arrhythmic Cardiac Death (2009) (86)
A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. (2002) (85)
Genome-Wide Association Study Identifies Variants at the IL18-BCO2 Locus Associated With Interleukin-18 Levels (2010) (85)
Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events (2006) (85)
Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. (2007) (85)
Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC‐Norfolk Prospective Population Study (2007) (85)
Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. (2001) (84)
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
Hormonal factors and risk of recurrent venous thrombosis: the Prevention of Recurrent Venous Thromboembolism trial (2006) (84)
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. (2016) (84)
Inflammatory markers and coronary heart disease (2002) (84)
Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata. (2012) (83)
Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis (2016) (83)
Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. (2016) (83)
High levels of plasma C-reactive protein and future risk of age-related cataract. (1999) (83)
Is C-Reactive Protein Specific for Vascular Disease in Women? (2002) (83)
Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor (1992) (83)
’ Consensus : Periodontitis and Atherosclerotic Cardiovascular Disease † (2009) (82)
A Meta-Analysis of Candidate Gene Polymorphisms and Ischemic Stroke in 6 Study Populations: Association of Lymphotoxin-Alpha in Nonhypertensive Patients (2009) (82)
Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. (2012) (81)
D‐dimer, factor VIII coagulant activity, low‐intensity warfarin and the risk of recurrent venous thromboembolism (2006) (81)
High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. (2007) (80)
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. (2013) (80)
Should Aspirin Be Used for Primary Prevention in the Post-Statin Era? (2018) (80)
Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study (2007) (80)
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy (2010) (79)
Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. (2007) (78)
C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference? (2006) (78)
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies (2018) (78)
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies (2018) (78)
Discovery and replication of novel blood pressure genetic loci in the Women's Genome Health Study (2011) (78)
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial (2015) (78)
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease (2017) (78)
Polymorphisms and haplotypes of the estrogen receptor-beta gene (ESR2) and cardiovascular disease in men and women. (2007) (78)
Metabolic Syndrome, Inflammation, and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study (2009) (78)
Stress-Associated Neurobiological Pathway Linking Socioeconomic Disparities to Cardiovascular Disease. (2019) (77)
Associations of Mitochondrial and Nuclear Mitochondrial Variants and Genes with Seven Metabolic Traits. (2019) (77)
Tracing Sub-Structure in the European American Population with PCA-Informative Markers (2008) (77)
Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. (2019) (77)
A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration. (2006) (76)
Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (2015) (75)
A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. (2016) (75)
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. (1990) (75)
Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. (2008) (74)
Influence of Genetic Variation in the C‐Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia (2006) (74)
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? (2013) (74)
The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial (2012) (73)
High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. (2001) (73)
Genome-Wide Association Study for Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort Studies: The CHARGE Consortium (2013) (73)
Endophenotype Network Models: Common Core of Complex Diseases (2016) (72)
Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. (2020) (72)
Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. (2004) (72)
Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. (1997) (72)
Toll-like Receptor 4 Asp299Gly Gene Polymorphism and Risk of Atherothrombosis (2005) (72)
Association of Variation at the ABO Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and Soluble E-selectin: A Meta-Analysis (2011) (72)
Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. (1997) (71)
High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention (2015) (71)
Atherosclerosis: the path from genomics to therapeutics. (2007) (70)
Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond (2018) (70)
Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence: Prospective Data From the Women’s Health Study (2018) (69)
High-Sensitivity C-Reactive Protein and Cognitive Function in Older Women (2006) (69)
Aspirin Has A Gender-Dependent Impact on Antiinflammatory 15-Epi-Lipoxin A4 Formation: A Randomized Human Trial (2005) (69)
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy (2011) (69)
Ventricular Arrhythmias in Trials of Thrombolytic Therapy for Acute Myocardial Infarction A Meta‐Analysis (1993) (69)
Associations of autozygosity with a broad range of human phenotypes (2019) (68)
Large-Scale Trials of Thrombolytic Therapy for Acute Myocardial Infarction: GISSI-2, ISIS-3, and GUSTO-1 (1993) (68)
PROTEIN-CODING VARIANTS IMPLICATE NOVEL GENES RELATED TO LIPID HOMEOSTASIS CONTRIBUTING TO BODY FAT DISTRIBUTION (2018) (67)
Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. (2012) (67)
Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes (2019) (66)
Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events (2002) (66)
Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. (2009) (66)
Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. (2016) (65)
Genetic loci associated with circulating phospholipid trans fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. (2015) (65)
A saturated map of common genetic variants associated with human height (2022) (65)
Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity (2019) (65)
Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women (2004) (65)
Smoking, Smoking Cessation, and Risk for Symptomatic Peripheral Artery Disease in Women (2011) (64)
Comparison of associations of adherence to a Dietary Approaches to Stop Hypertension (DASH)‐style diet with risks of cardiovascular disease and venous thromboembolism (2012) (64)
Effects of long-term averaging of quantitative blood pressure traits on the detection of genetic associations. (2014) (64)
Predisposing Factors Associated With Development of Persistent Compared With Paroxysmal Atrial Fibrillation (2014) (64)
Targeting inflammatory pathways for the treatment of cardiovascular disease. (2014) (64)
Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome. (2010) (64)
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles (2021) (64)
Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. (2018) (64)
Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis (2019) (63)
Circulating Blood Markers and Functional Impairment in Peripheral Arterial Disease (2008) (63)
Association of adiponectin gene variations with risk of incident myocardial infarction and ischemic stroke: a nested case-control study. (2006) (63)
C-reactive protein and risks of future myocardial infarction and thrombotic stroke. (1998) (63)
Novel risk factors and markers for coronary disease. (2000) (63)
Risk factor criteria. (2004) (63)
C-reactive protein in the prediction of rheumatoid arthritis in women. (2006) (63)
Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. (2002) (62)
Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. (1992) (62)
Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. (2002) (61)
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women (2008) (61)
Adverse Effects of Low-Dose Methotrexate (2020) (61)
Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein (2006) (60)
Lipid levels and the risk of hemorrhagic stroke among women (2019) (60)
Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. (2002) (60)
Perceptions of race/ethnic discrimination in relation to mortality among Black women: results from the Black Women's Health Study. (2010) (60)
A principal component meta-analysis on multiple anthropometric traits identifies novel loci for body shape (2016) (59)
Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease (2018) (59)
A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. (2001) (59)
The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. (1991) (59)
Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. (2001) (59)
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). (2012) (58)
Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study (2009) (58)
Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. (2003) (58)
IL-1β Inhibition Reduces Atherosclerotic Inflammation in HIV Infection. (2018) (58)
Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. (2007) (58)
C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. (2002) (57)
Association of adiposity genetic variants with menarche timing in 92,105 women of European descent. (2013) (57)
Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. (2017) (57)
The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. (2010) (57)
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. (2001) (57)
Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. (2020) (57)
Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. (2014) (57)
Gamma-glutamyl carboxylase and its influence on warfarin dose (2010) (56)
Polymorphisms of the Phosphodiesterase 4D, cAMP-Specific (PDE4D) Gene and Risk of Ischemic Stroke: A Prospective, Nested Case–Control Evaluation (2006) (56)
Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease. (2006) (56)
Cerebral small vessel disease genomics and its implications across the lifespan (2020) (56)
A trial-based approach to statin guidelines. (2013) (56)
Cerebral small vessel disease genomics and its implications across the lifespan (2020) (56)
Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. (2001) (56)
Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. (2015) (55)
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. (2007) (55)
Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. (1991) (55)
Multi‐locus candidate gene polymorphisms and risk of myocardial infarction: a population‐based, prospective genetic analysis (2006) (55)
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study. (2006) (55)
Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium (2018) (54)
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial (2015) (54)
D‐Dimer and Inflammatory Markers as Predictors of Functional Decline in Men and Women with and without Peripheral Arterial Disease (2005) (54)
Connecting the role of C‐reactive protein and statins in cardiovascular disease (2003) (54)
C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts. (2013) (54)
and Attilio Maseri Inflammation and Atherosclerosis (2002) (54)
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. (2010) (53)
Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women. (2020) (53)
Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals (2020) (53)
From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? (2020) (53)
Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins (2017) (52)
Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies (2013) (52)
Abstract 15111: TET2-Driven Clonal Hematopoiesis Predicts Enhanced Response to Canakinumab in the CANTOS Trial: An Exploratory Analysis (2018) (52)
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events☆ (2003) (52)
Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. (2011) (52)
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? (2003) (51)
Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet (2018) (51)
Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention (2011) (51)
Plasma C-Reactive Protein and Risk of Breast Cancer in Two Prospective Studies and a Meta-analysis (2015) (51)
Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. (2015) (51)
Increased inflammatory markers in children with familial hypercholesterolaemia (2006) (51)
New Blood Pressure–Associated Loci Identified in Meta-Analyses of 475 000 Individuals (2017) (50)
Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women’s Health Initiative (2018) (50)
Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study (2008) (50)
Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study (2019) (50)
Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. (2003) (50)
Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? (1993) (50)
High-sensitivity C-reactive protein as a predictor of all-cause mortality: implications for research and patient care. (2008) (49)
Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). (2014) (49)
Relationship of Interleukin-1 Blockade With Incident Gout and Serum Uric Acid Levels (2018) (49)
Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. (2011) (48)
Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects. (1999) (48)
Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. (2004) (48)
Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. (2015) (48)
High-Molecular-Weight and Total Adiponectin Levels and Incident Symptomatic Peripheral Artery Disease in Women: A Prospective Investigation (2011) (48)
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. (2022) (48)
Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. (2021) (47)
Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study (2014) (47)
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. (2022) (47)
Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. (2016) (47)
Selectivity in Genetic Association with Sub-classified Migraine in Women (2014) (46)
Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism (2007) (46)
Prediction of incident hypertension risk in women with currently normal blood pressure. (2009) (46)
Genome-wide Trans-ethnic Meta-analysis Identifies Seven Genetic Loci Influencing Erythrocyte Traits and a Role for RBPMS in Erythropoiesis. (2017) (46)
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities (2010) (46)
Unraveling Vascular Inflammation: From Immunology to Imaging. (2017) (46)
Genetic variants at 2 q 24 are associated with susceptibility to type 2 diabetes (2010) (46)
Identifying Novel Gene Variants in Coronary Artery Disease and Shared Genes With Several Cardiovascular Risk Factors. (2016) (45)
Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study (2017) (45)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2019) (45)
Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. (2008) (44)
Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. (2002) (44)
Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology? (2002) (44)
Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease (2005) (44)
Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9 p 21 . 3 (2008) (44)
A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women (2009) (44)
Measures to assess the prognostic ability of the stratified Cox proportional hazards model (2009) (44)
DNA mismatch repair gene MSH6 implicated in determining age at natural menopause (2013) (44)
Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial (2016) (44)
C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. (2013) (44)
SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function. (2017) (44)
Inflammatory markers and coronary heart disease. (2002) (44)
Plasma Levels of the Proinflammatory Chitin‐Binding Glycoprotein YKL‐40, Variation in the Chitinase 3‐Like 1 Gene (CHI3L1), and Incident Cardiovascular Events (2014) (44)
Using genetics to test the causal relationship of total adiposity and periodontitis: Mendelian randomization analyses in the Gene-Lifestyle Interactions and Dental Endpoints (GLIDE) Consortium. (2015) (44)
An X Chromosome Association Scan of the Norfolk Island Genetic Isolate Provides Evidence for a Novel Migraine Susceptibility Locus at Xq12 (2012) (44)
Blood Pressure and Risk of Secondary Cardiovascular Events in Women: The Women’s Antioxidant Cardiovascular Study (WACS) (2004) (43)
A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. (2003) (43)
Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women (2014) (43)
Assessment of genetic markers for coronary thrombosis: promise and precaution (1999) (43)
Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial (2015) (43)
Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. (2018) (43)
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. (2014) (43)
Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study. (2008) (43)
How to translate clinical trial results into gain in healthy life expectancy for individual patients (2016) (42)
Polymorphisms in the Advanced Glycosylation End Product–Specific Receptor Gene and Risk of Incident Myocardial Infarction or Ischemic Stroke (2006) (42)
Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A2 Mass and Activity at Baseline and After Rosuvastatin Therapy (2012) (42)
An Evaluation of Candidate Genes of Inflammation and Thrombosis in Relation to the Risk of Venous Thromboembolism: The Women's Genome Health Study (2009) (42)
Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of C-reactive protein and D-dimer. (2006) (42)
Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly. (1998) (42)
Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program. (2005) (42)
Effects of a single, daily alcoholic beverage on lipid and hemostatic markers of cardiovascular risk. (1997) (42)
The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study (2019) (42)
Inflammation, C-reactive protein, and cardiovascular disease: moving past the marker versus mediator debate. (2014) (41)
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. (2018) (41)
The Budd-Chiari syndrome and hepatic veno-occlusive disease. Recognition and treatment. (1990) (40)
Dietary fatty acids modulate associations between genetic variants and circulating fatty acids in plasma and erythrocyte membranes: Meta-analysis of nine studies in the CHARGE consortium. (2015) (40)
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. (2011) (40)
Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. (2009) (40)
Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. (2004) (40)
Markers of Inflammation and Incident Breast Cancer Risk in the Women’s Health Study (2018) (40)
Physical Activity Modifies the Effect of LPL, LIPC, and CETP Polymorphisms on HDL-C Levels and the Risk of Myocardial Infarction in Women of European Ancestry (2011) (40)
Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosis. (2004) (39)
Interaction between inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction in the Physician’s Health Study (2005) (39)
Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels (2011) (39)
Tomato-based food products are related to clinically modest improvements in selected coronary biomarkers in women. (2012) (39)
Association of renin–angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study (2008) (39)
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. (2021) (39)
Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial (1998) (39)
Genetic loci associated with circulating levels of very long-chain saturated fatty acids[S] (2015) (38)
Genetic determinants of C-reactive protein (2007) (38)
Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women (2009) (38)
Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. (2017) (38)
Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein (2012) (38)
Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers (2014) (38)
Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). (2011) (38)
Polymorphisms of prostaglandin‐endoperoxide synthase 2 gene, and prostaglandin‐E receptor 2 gene, C‐reactive protein concentrations and risk of atherothrombosis: a nested case–control approach (2006) (38)
Relative leukocyte telomere length and risk of incident ischemic stroke in men: a prospective, nested case-control approach. (2010) (38)
Rare, low frequency and common coding variants in CHRNA5 and their contribution to nicotine dependence in European and African Americans (2016) (37)
C-reactive protein and coronary heart disease. (2004) (37)
Hemostatic risk factors for coronary heart disease. (1991) (37)
Correction: The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study (2016) (37)
Differential Citation Rates of Major Cardiovascular Clinical Trials According to Source of Funding: A Survey From 2000 to 2005 (2008) (37)
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial (2020) (37)
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. (2007) (37)
Anti-Platelet Effects of 100 mg Alternate Day Oral Aspirin: A Randomized, Double-Blind, Placebo-Controlled Trial of Regular and Enteric Coated Formulations in Men and Women (1996) (37)
Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension (2007) (37)
Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease (1997) (37)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6 q 14 and 20 q 11 (2012) (36)
Toxic effects of herbal teas. (1987) (36)
A common missense variant of LILRB5 is associated with statin intolerance and myalgia (2017) (36)
Rare coding variants and X-linked loci associated with age at menarche (2015) (36)
An epidemiologic assessment of thrombotic risk factors for cardiovascular disease (1992) (36)
Genetic variants of 11 telomere-pathway gene loci and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study. (2011) (36)
C-reactive protein gene variation and type 2 diabetes mellitus: a case-control study. (2008) (36)
Common variants in Mendelian kidney disease genes and their association with renal function. (2013) (35)
Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. (2008) (35)
Association between consumption of beer, wine, and liquor and plasma concentration of high-sensitivity C-reactive protein in women aged 39 to 89 years. (2005) (35)
A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. (2006) (34)
Dairy Consumption and Body Mass Index Among Adults: Mendelian Randomization Analysis of 184802 Individuals from 25 Studies. (2018) (34)
Effect of Dietary Composition of Weight Loss Diets on High Sensitivity C-Reactive Protein: The Randomized POUNDS LOST Trial (2012) (34)
High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect (2013) (34)
Polymorphisms in Catechol-O-Methyltransferase Modify Treatment Effects of Aspirin on Risk of Cardiovascular Disease (2014) (34)
Reclassification Calculations for Persons With Incomplete Follow-up (2010) (34)
Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease (2004) (34)
Haplotype Analysis of the β2 Adrenergic Receptor Gene and Risk of Myocardial Infarction in Humans (2005) (34)
A genome-wide analysis of 'Bounty' descendants implicates several novel variants in migraine susceptibility (2012) (34)
The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP? (2008) (34)
Awareness, Accuracy, and Predictive Validity of Self-Reported Cholesterol in Women (2007) (34)
Association Between High-Sensitivity C-Reactive Protein and Total Stroke by Hypertensive Status Among Men (2015) (33)
Coronavirus 2019 Disease (COVID‐19), Systemic Inflammation, and Cardiovascular Disease (2020) (33)
Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21 483 women (2013) (33)
Effects of Interleukin-1 β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inﬂammatory Risk A Secondary Analysis of CANTOS (2019) (33)
Supplementation with beta-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. (1995) (32)
Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. (1997) (32)
Genetic variants within the interleukin-1 gene cluster, and risk of incident myocardial infarction, and ischemic stroke: a nested case-control approach. (2008) (32)
High sensitivity C-reactive protein in clinical practice. (2003) (32)
Plasma Inflammatory Markers and the Risk of Developing Hypertension in Men (2015) (32)
A Response to Holding GUSTO Up to the Light (1994) (32)
Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in southeastern New England. (2008) (32)
Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement (2020) (32)
Canakinumab for Residual Inflammatory Risk. (2017) (32)
Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk (2019) (32)
Current issues concerning thrombolytic therapy for acute myocardial infarction. (1995) (31)
Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women. (2012) (31)
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins (2016) (31)
Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. (2001) (31)
Common genetic variations in the vitamin D pathway in relation to blood pressure. (2014) (31)
Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction: Results From the VIRGO (Variation in Recovery Role of Gender on Outcomes of Young Acute Myocardial Infarction Patients) Study (2017) (31)
The editor's roundtable: psoriasis, inflammation, and coronary artery disease. (2008) (31)
Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis (2001) (31)
Inflammation, Aspirin, and Cardiovascular Disease (1997) (31)
Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X. (2013) (30)
Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use? (2016) (30)
Polymorphism in the &bgr;2-Adrenergic Receptor and Lipoprotein Lipase Genes as Risk Determinants for Idiopathic Venous Thromboembolism: A Multilocus, Population-Based, Prospective Genetic Analysis (2006) (30)
Anti‐inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials (2018) (30)
Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? (2018) (30)
The JUPITER Trial: responding to the critics. (2010) (30)
Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. (2007) (29)
Streptokinase therapy and cholesterol embolization. (1989) (29)
Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour (2021) (29)
Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes (2018) (29)
A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine (2020) (29)
Statins for stroke: the second story? (2001) (29)
Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans (2004) (29)
Interaction of methylation-related genetic variants with circulating fatty acids on plasma lipids: a meta-analysis of 7 studies and methylation analysis of 3 studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium. (2016) (29)
Quality of dietary fat and genetic risk of type 2 diabetes: individual participant data meta-analysis (2019) (29)
Neighborhood Socioeconomic Status in Relation to Serum Biomarkers in the Black Women’s Health Study (2016) (28)
Hyperlipidemia as an Instigator of Inflammation: Inaugurating New Approaches to Vascular Prevention (2012) (28)
High-sensitivity C-reactive protein (2004) (28)
A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure. (2019) (28)
Coronary artery calcium scanning should be used for primary prevention: pros and cons. (2012) (28)
Genetic variants in eleven telomere-associated genes and the risk of incident cardio/cerebrovascular disease: The Women's Genome Health Study. (2011) (28)
Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. (2017) (28)
Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications. (2017) (28)
B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. (2014) (27)
Relation of renal function to risk for incident atrial fibrillation in women. (2012) (27)
Thrombosis and Thromboembolism (2002) (27)
A first update on mapping the human genetic architecture of COVID-19 (2022) (27)
Multimarker Approach Predicts Adverse Cardiovascular Events in Women Evaluated for Suspected Ischemia: Results from the National Heart, Lung, and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation (2009) (27)
Inflammatory and Thrombotic Blood Markers and Walking‐Related Disability in Men and Women with and Without Peripheral Arterial Disease (2004) (27)
Herbal toxicity and fatal hepatic failure. (1999) (27)
Two common gene variants on chromosome 9 and risk of atherothrombosis. (2007) (27)
A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. (2015) (26)
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". (2014) (26)
Circulating inflammatory and endothelial markers and risk of hypertension in white and black postmenopausal women. (2011) (26)
Stroke genetics informs drug discovery and risk prediction across ancestries (2022) (26)
C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment (2011) (26)
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (2018) (26)
Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality (2016) (26)
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 (2018) (25)
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? (1996) (25)
Tumour necrosis factor-α, inflammatory biomarkers, and atherogenesis (2002) (25)
Hemoglobin A1c, body mass index, and the risk of hypertension in women. (2011) (25)
Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. (2013) (25)
Should patients with rheumatoid arthritis receive statin therapy? (2009) (25)
Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic disease. (1998) (25)
Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial. (2003) (25)
Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin. (2019) (25)
Corrigendum: Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine (2016) (25)
Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. (2020) (25)
Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study (2017) (24)
Physical activity and inflammation in a multiethnic cohort of women. (2012) (24)
A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100. (1993) (24)
Improved health benefits of increased use of thrombolytic therapy. (1994) (24)
Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose (2020) (24)
AJC editor's consensus: rheumatoid arthritis and atherosclerotic cardiovascular disease. (2010) (24)
A Prospective Evaluation of the CD14 and CD18 Gene Polymorphisms and Risk of Stroke (2002) (24)
Hemoglobin A1c Concentrations and Risk of Colorectal Cancer in Women (2005) (24)
C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. (2002) (23)
Effects of Interleukin-1 (cid:1) Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen A Phase IIb Randomized, Placebo-Controlled Trial (2012) (23)
Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism. (2008) (23)
Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: data from the Women's Genome Health Study. (2009) (23)
Association between polymorphisms in the β2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women (2009) (23)
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy (2006) (23)
Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation (2000) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Psoriasis, inflammation, and vascular risk: a problem more than skin deep? (2010) (23)
Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease. (2011) (23)
Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. (2010) (23)
Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache (2020) (23)
Genetic Determinants of Cardiovascular Events among Women with Migraine: A Genome-Wide Association Study (2011) (23)
Association of Birth Weight With Type 2 Diabetes and Glycemic Traits (2019) (23)
Surgical management of carcinoid heart disease. (1991) (22)
The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta‐analysis of randomized controlled trials (2017) (22)
Comparing Cardiovascular Risk Prediction Scores (2015) (22)
Response to Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. (2014) (22)
The Pooled Cohort Equations 3 Years On: Building a Stronger Foundation. (2016) (22)
Echocardiographic diagnosis of congential absence of the pericardium in a patient with VATER association defects (1994) (21)
Vasectomy and subsequent cardiovascular disease in US physicians. (1999) (21)
Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients. (2003) (21)
Health hazards of unusual herbal teas. (1989) (21)
An Empirical Comparison of Joint and Stratified Frameworks for Studying G × E Interactions: Systolic Blood Pressure and Smoking in the CHARGE Gene‐Lifestyle Interactions Working Group (2016) (21)
C‐reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype‐based analysis (2004) (20)
Renin–angiotensin and endothelial nitric oxide synthase gene polymorphisms are not associated with the risk of incident type 2 diabetes mellitus: a prospective cohort study (2008) (20)
Association Between a Literature-Based Genetic Risk Score and Cardiovascular Events in Women (2010) (20)
Smoking, Smoking Status, and Risk for Symptomatic Peripheral Artery Disease in Women: A Cohort Study (2011) (20)
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2017) (20)
A prospective replication study of five gene variants previously associated with risk of myocardial infarction (2006) (20)
C-reactive protein and prognosis after percutaneous coronary intervention. (2002) (20)
Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: a prospective analysis of the Women's Health Study. (2008) (20)
Clinical Characteristics of Nonfatal Myocardial Infarction Among Individuals on Prophylactic Low‐Dose Aspirin Therapy (1991) (20)
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy (2022) (19)
Vitamin D–Associated Genetic Variation and Risk of Breast Cancer in the Breast and Prostate Cancer Cohort Consortium (BPC3) (2014) (19)
Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease (2005) (19)
Lipoproteins in chronic kidney disease: from bench to bedside. (2021) (19)
Reproductive aging-associated common genetic variants and the risk of breast cancer (2012) (19)
Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. (2003) (19)
Primary and Secondary Prevention of Coronary Heart Disease (2012) (19)
Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. (2019) (19)
Moving toward new statin guidelines in a post-JUPITER world: Principles to consider (2009) (19)
Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes (2011) (19)
Ranking and characterization of established BMI and lipid associated loci as candidates for gene-environment interactions (2017) (19)
Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis (2021) (19)
Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. (2021) (19)
COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical Trials. (2019) (18)
A Prospective Evaluation of the Interleukin-1 Receptor Antagonist Intron 2 Gene Polymorphism and the Risk of Myocardial Infarction (2001) (18)
The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. (2020) (18)
Long‐term low‐dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes (2004) (18)
Comparison of characteristics of future myocardial infarctions in women with baseline high versus baseline low levels of high-sensitivity C-reactive protein. (2007) (18)
Lipoprotein (a), Lipids, Aspirin, and Risk of Myocardial Infarction in the Physician's Health Study (1998) (18)
Left ventricular hemangioma in Kasabach-Merritt syndrome. (1991) (18)
Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease? (2016) (17)
High prevalence of metabolic syndrome among young women with nonfatal myocardial infarction. (2004) (17)
The editor's roundtable: the JUPITER trial--initial results and clinical implications. (2009) (17)
Publisher Correction: Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits (2018) (17)
Association between Vitamin D Genetic Risk Score and Cancer Risk in a Large Cohort of U.S. Women (2018) (17)
Risk Markers for Atherothrombotic Disease (2012) (17)
Association Between Polymorphisms in the β2‐adrenoceptor Gene and Migraine in Women (2009) (17)
Association of the Mediterranean Diet With Onset of Diabetes in the Women’s Health Study (2020) (17)
Abstract 4992: Cardiovascular Disease Risk Prediction with and without Knowledge of Genetic Variation at Chromosome 9p21.3: The Women's Genome Health Study (2008) (17)
Comparison of Lifestyle-Based and Traditional Cardiovascular Disease Prediction in a Multiethnic Cohort of Nonsmoking Women (2014) (17)
Gene Variation of the Transient Receptor Potential Cation Channel, Subfamily M, Member 7 (TRPM7), and Risk of Incident Ischemic Stroke: Prospective, Nested, Case-Control Study (2009) (17)
Rosuvastatin for primary prevention in older individuals with high C-reactive protein and low LDL levels: exploratory analysis of a randomized trial (2010) (17)
Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. Discussion and Commentary (2007) (17)
Gene Variation of Endoplasmic Reticulum Aminopeptidases 1 and 2, and Risk of Blood Pressure Progression and Incident Hypertension among 17,255 Initially Healthy Women (2018) (16)
Cardiovascular inflammation in healthy women: multilevel associations with state-level prosperity, productivity and income inequality (2012) (16)
2417Elevated interleukin-6 and interleukin-18 concentrations predict residual inflammatory risk both before and after interleukin-1beta inhibition with canakinumab (2019) (16)
Analysis of potential protein-modifying variants in 9000 endometriosis patients and 150000 controls of European ancestry (2017) (16)
What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy. (2012) (16)
Association of genetic variants with the metabolic syndrome in 20,806 white women: The Women's Health Genome Study. (2009) (16)
Genome-wide association meta-analysis of fish and EPA+DHA consumption in 17 US and European cohorts (2017) (16)
Plasma concentration of endogenous tissue plasminogen activator and the occurrence of future cardiovascular events (2005) (16)
Is venous thromboembolism a chronic inflammatory disease? (2015) (15)
GOSR2 Lys67Arg is associated with hypertension in whites. (2009) (15)
Refining the American guidelines for prevention of cardiovascular disease – Authors' reply (2014) (15)
Plasma Pentraxin 3 Levels Do Not Predict Coronary Events but Reflect Metabolic Disorders in Patients with Coronary Artery Disease in the CARE Trial (2014) (15)
Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach. (2009) (15)
Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease (2018) (15)
A large‐scale exome array analysis of venous thromboembolism (2019) (15)
The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation (2010) (15)
Tumour necrosis factor-alpha, inflammatory biomarkers, and atherogenesis. (2002) (15)
Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women (2018) (15)
Physical Activity and Incident Cardiovascular Disease in Women: Is the Relation Modified by Level of Global Cardiovascular Risk? (2018) (14)
The relative importance of systolic versus diastolic blood pressure control and incident symptomatic peripheral artery disease in women (2011) (14)
Prospective study of plasma homocysteine, its dietary determinants, and risk of age-related macular degeneration in men (2018) (14)
Genome-wide association analyses of physical activity and sedentary behavior provide insights into underlying mechanisms and roles in disease prevention (2022) (14)
Genetic analysis of over one million people identifies 535 novel loci for blood pressure (2017) (14)
Abstract 10170: Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (2013) (14)
From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? (2021) (14)
Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. (2005) (14)
Genetic Studies of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity (2020) (14)
Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease. (2019) (14)
Stimulating high impact HIV-related cardiovascular research: recommendations from a multidisciplinary NHLBI Working Group on HIV-related heart, lung, and blood disease. (2015) (14)
Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events (2014) (14)
Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study). (2015) (14)
Pathogenesis and Pathology of Coronary Heart Disease Syndromes (1999) (14)
Plasma adiponectin and the risk of hypertension in white and black postmenopausal women. (2012) (13)
Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. (2016) (13)
Association of High‐Density Lipoprotein‐Cholesterol Versus Apolipoprotein A‐I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer‐Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study (2017) (13)
Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers. (2022) (13)
Establishing a clinical basis for hsCRP in the prevention and treatment of cardiovascular disease. (2010) (13)
Genetic Variation of the Androgen Receptor and Risk of Myocardial Infarction and Ischemic Stroke in Women (2008) (13)
Lipid-Lowering and Anti-Inflammatory Benefits of Statin Therapy: More Than Meets the Plaque. (2017) (13)
Familial occurrence of neurocardiogenic syncope. (1994) (13)
Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates: A Next Step for Atherothrombosis Treatment and Prevention. (2021) (13)
C-reactive protein and cardiovascular risk in the Framingham Study. (2006) (13)
Blood levels of homocysteine and atherosclerotic vascular disease (2000) (13)
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. (2003) (13)
The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation (2018) (13)
Therapeutic targeting of inflammation in atherosclerosis: we are getting closer. (2012) (13)
Hypothyroidism and kidney function - a Mendelian Randomization study. (2020) (13)
Pulmonary Adverse Events in Patients Receiving Low‐Dose Methotrexate in the Randomized, Double‐Blind, Placebo‐Controlled Cardiovascular Inflammation Reduction Trial (2020) (13)
Factor V Leiden is not a risk factor for myocardial infarction among young women. (1999) (13)
Association Between 9 p 21 Genomic Markers and Heart Disease : A Meta-analysis (2010) (13)
Mitochondrial uncoupling protein gene cluster variation (UCP2-UCP3) and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study. (2011) (13)
Dairy Intake and Body Composition and Cardiometabolic Traits among Adults: Mendelian Randomization Analysis of 182041 Individuals from 18 Studies. (2019) (13)
Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. (2007) (13)
Inherited risk factors for venous thromboembolism: implications for clinical practice. (2002) (13)
Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate: AIDS Clinical Trials Group Study A5314 (2018) (12)
Aspirin, platelet aggregation, and the circadian variation of acute thrombotic events. (1991) (12)
A Prospective Assessment of the Y 402 H Variant in Complement Factor H , Genetic Variants in C-Reactive Protein , and Risk of Age-Related Macular Degeneration (2006) (12)
Prospective Study of Plasma Homocysteine Level and Risk of Age-Related Macular Degeneration in Women (2015) (12)
A Prospective Evaluation of the Heat Shock Protein 70 Gene Polymorphisms and the Risk of Stroke (2002) (12)
Inflammation, high-sensitivity C-reactive protein, and vascular protection. (2010) (12)
Catechol-O-methyltransferase association with hemoglobin A1c. (2016) (12)
Population-based genomewide genetic analysis of common clinical chemistry analytes. (2009) (12)
Current and future perspectives on antithrombotic therapy of acute myocardial infarction. (1995) (12)
Publisher Correction: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (2019) (12)
Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. (2020) (12)
Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation (1999) (12)
Anti-inflammatory therapies for cardiovascular disease (2018) (11)
Hemostatic factors and the risk of myocardial infarction. (1995) (11)
Intercellular Adhesion Molecule 1 (ICAM1) Lys56Met and Gly241Arg Gene Variants, Plasma-Soluble ICAM1 Concentrations, and Risk of Incident Cardiovascular Events in 23 014 Initially Healthy White Women (2007) (11)
Adverse Effects of Low‐Dose Methotrexate in a Randomized Double‐Blind Placebo‐Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial (2020) (11)
An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. (1995) (11)
Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study. (2014) (11)
Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism (2005) (11)
Effects of Interleukin-1β Inhibition on Incident Anemia (2020) (11)
High-sensitivity C-reactive protein, vascular imaging, and vulnerable plaque: more evidence to support trials of antiinflammatory therapy for cardiovascular risk reduction. (2011) (11)
Aspirin, postmenopausal hormones, and C-reactive protein. (2002) (10)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (10)
Statin therapy for low-LDL, high-hsCRP patients: from JUPITER to CORONA. (2010) (10)
Age and thrombolytic therapy. (1996) (10)
Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries (2019) (10)
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche DTU Orbit (05/11/2017) (2014) (10)
Discordance of LDL Cholesterol with Alternative LDL-Related Measures and Future Coronary Events (2013) (10)
Perspectives from NHLBI Global Health Think Tank Meeting for Late Stage (T4) Translation Research. (2017) (10)
Expanding options for scientific publication: is more always better? (2013) (10)
Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. (2016) (10)
Biomarkers and functional outcomes from ischaemic cerebral events in women: a prospective cohort study (2013) (10)
Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. (2018) (10)
Additive and Multiplicative Interactions Between Genetic Risk Score and Family History and Lifestyle in Relation to Risk of Type 2 Diabetes (2019) (10)
Antithrombotic therapy for acute myocardial infarction. (1995) (10)
HbA1c Predicts Diabetes but not Cardiovascular Disease in Non- Diabetic Women (2008) (10)
Role of Rare and Low-Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels (2020) (10)
Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women (2021) (10)
Will Reducing Inflammation Reduce Vascular Event Rates? (2017) (10)
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease (2022) (10)
Gene-educational attainment interactions in a multi-ancestry genome-wide meta-analysis identify novel blood pressure loci (2020) (9)
No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects (2014) (9)
The role of C-reactive protein in cardiovascular disease risk (2000) (9)
Tissue-Specific Alteration of Metabolic Pathways Influences Glycemic Regulation (2019) (9)
Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial (2020) (9)
Correction: Genome-wide physical activity interactions in adiposity ― A meta-analysis of 200,452 adults (2017) (9)
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies (2019) (9)
Integrating children’s physical activity enjoyment into public health dialogue (United States) (2019) (9)
Effect of Rosuvastatin on Hemoglobin Levels in Patients With Anemia and Low‐Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial (2011) (9)
Is the adiposity‐associated FTO gene variant related to all‐cause mortality independent of adiposity? Meta‐analysis of data from 169,551 Caucasian adults (2015) (9)
Inherited risk factors for venous thromboembolism: implications for clinical practice. (2000) (9)
Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease (2020) (9)
Interleukin-1 inhibition and ischaemic stroke: has the time for a major outcomes trial arrived? (2018) (9)
Targeting Interleukin-1 and Interleukin-6: The Time Has Come to Aggressively Address Residual Inflammatory Risk. (2020) (9)
Genome-wide analysis identifies genetic effects on reproductive success and ongoing natural selection at the FADS locus (2020) (9)
Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial (2007) (9)
O3-01-02 Plasma cholesterol levels and cognitive function in aging women (2004) (9)
Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis (2017) (8)
Are associations between infection and coronary disease causal or due to confounding? (1999) (8)
Human Papilloma Virus Infection. (2019) (8)
False positive mononucleosis screening test results associated with Klebsiella hepatic abscess. (1990) (8)
Lack of Association Between Genetic Variation in 9 Innate Immunity Genes and Baseline CRP Levels (2006) (8)
Family History of MI, Smoking, and Risk of Periodontal Disease (2018) (8)
Abstract 17731: Protein Glycan Side-Chains, Rosuvastatin Therapy, and Incident Vascular Events: An Analysis from the JUPITER Trial (2014) (8)
Erratum to: Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits : (Nature Genetics, (2018), 50, 10, (1412-1425), 10.1038/s41588-018-0205-x) (2018) (8)
Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women’s Genome Health Study (2019) (8)
Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R (2021) (8)
C-reactive protein in 2005. Interview by Peter C. Block. (2005) (8)
Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. (2018) (8)
JCL Roundtable: is inflammation a future target in preventing arteriosclerotic cardiovascular disease. (2015) (8)
Mean telomere length and risk of incident venous thromboembolism: a prospective, nested case-control approach. (2009) (8)
Generation Scotland (2015) (8)
Genetic variation of fifteen folate metabolic pathway associated gene loci and the risk of incident head and neck carcinoma: the Women's Genome Health Study. (2013) (7)
Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity (2017) (7)
Pulmonary adverse events of low-dose methotrexate in the randomized double-blind placebo-controlled Card. (2020) (7)
Use of aspirin as primary prevention of cardiovascular events. (2006) (7)
Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial (2021) (7)
Nontraditional coronary risk factors and vascular biology: the frontiers of preventive cardiology. (1998) (7)
Prospective Evaluation of the Alcohol Dehydrogenase &ggr;1/&ggr;2 Gene Polymorphism and Risk of Stroke (2004) (7)
Association of HDL Cholesterol with Incident Cardiovascular Events by LDL Cholesterol and Apolipoprotein B100 in Women (2011) (7)
Lipoprotein(a) and risks of cardiovascular disease. (1994) (7)
Interpretation of Mendelian randomization studies and the search for causal pathways in atherothrombosis: the need for caution. (2010) (7)
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. (2022) (7)
Smoking, Smoking Cessation and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study (2011) (7)
C-reactive protein in the Heart Protection Study (2011) (7)
HDL cholesterol, size, particle number, and residual vascular risk after potent statin therapy: the JUPITER trial (2013) (7)
Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein–Related Measures (2015) (6)
Geographic Variation in Cardiovascular Inflammation among Healthy Women in the Women's Health Study (2011) (6)
Endogenous fibrinolytic function and risks of future myocardial infarction and stroke: observations from the Physicians' Health Study (1997) (6)
Inflammation, venous thromboembolism, and what we can do about it (2018) (6)
Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk—A Review (2019) (6)
Inflammation, cardiovascular disease and cancer: moving toward predictive medicine (2017) (6)
Atrial fibrillation induced by breath spray. (1989) (6)
Novel Targets for Atheroprotection From C-Reactive Protein to Interleukin-6 to Interleukin-1 : Moving Upstream To Identify (6)
Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy. (2021) (6)
Cholesterol Evaluation in Young Adults: Absence of Clinical Trial Evidence Is Not a Reason to Delay Screening (2017) (6)
Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis (1999) (6)
Biomarkers for Cardiovascular Screening: Progress or Passé? (2017) (6)
JUPITER, rosuvastatin, and the European Medicines Agency (2010) (6)
Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy. (2016) (6)
A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids (2021) (6)
Abstract 18807: Novel Protein Glycan Derived Biomarker is Associated With Incident Diabetes (2013) (6)
Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood (2020) (5)
Using inflammatory biomarkers to guide lipid therapy (2008) (5)
Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. (2021) (5)
Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors (2005) (5)
Genetic loci associated with prevalent and incident myocardial infarction and coronary heart disease in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (2020) (5)
Genome-wide association study provides new insights into the genetic architecture and pathogenesis of heart failure (2019) (5)
Hepatic veno-occlusive disease and herbal teas. (1989) (5)
Lipid-Modifying Therapies and Risk of Pancreatitis (2012) (5)
More on the GUSTO Trial (1994) (5)
Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors (2022) (5)
Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol. (2021) (5)
Plasma Concentration of Interleukin-6 and C-reactive Protein and the Risk of Developing Type 2 Diabetes Mellitus Among Healthy Middle-Aged Women (2001) (5)
Demystifying HDL Cholesterol-A "Human Knockout" to the Rescue? (2017) (5)
Lipids and cardiovascular disease 1 LDL cholesterol: controversies and future therapeutic directions (2014) (4)
Homocysteine, B Vitamins, MTHFR Genotype, and Incident Age-related Macular Degeneration. (2017) (4)
Genomic Biomarkers in Human Population Studies (2013) (4)
Role of Rare and Low Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels (2018) (4)
C-reactive Protein — a Prognostic Marker of Inflammation in Atherothrombosis (2001) (4)
Factor V Leiden and Recurrent Venous Thromboembolism (1996) (4)
Pharmacogenetics: the outlook for genetic testing in statin therapy (2005) (4)
Erratum to “A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infraction in middle-aged men”: [Atherosclerosis 161 (2002) 469–474] (2003) (4)
In ﬂ ammation, Immunity, and Infection in Atherothrombosis (2018) (4)
Incomplete financial disclosure for study of funding and outcomes in major cardiovascular trials. (2006) (4)
Is Statin Monotherapy the Perfect Polypill? (2016) (4)
Association of Physical Activity With Bioactive Lipids and Cardiovascular Events (2022) (4)
Apical wall stress by finite element analysis predicts subsequent left ventricular remodeling in the healing and early afterload reducing trial (1998) (4)
Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals (2022) (4)
Children’s physical activity levels in a sports-oriented summer day camp (2018) (4)
Clinician ’ s Guide to Reducing In ﬂ ammation to Reduce Atherothrombotic Risk (2018) (4)
Genome-wide association analysis identifies 27 novel loci associated with uterine leiomyomata revealing common genetic origins with endometriosis (2018) (4)
Targeting cytokine storm in COVID-19: what have we learned? (2021) (4)
Myocardial infarction in a 72-year-old woman with low LDL-C and increased hsCRP: implications for statin therapy. (2009) (4)
Coronary artery calcium scanning in primary prevention: a conversation with cardiology fellows. (2011) (4)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (4)
Homocysteine Is Associated With Future Venous Thromboembolism in 2 Prospective Cohorts of Women (2021) (4)
Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status. (2022) (4)
Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions (2021) (4)
Prospective evaluation of the alcohol dehydrogenase gamma1/gamma2 gene polymorphism and risk of stroke. (2004) (4)
CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia (2017) (4)
AIR POLLUTION AND MARKERS OF CARDIOVASCULAR RISK (2004) (4)
Informative Neutral Studies Matter-Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention. (2016) (4)
Supplementary Material 5 (2014) (3)
Association of Genetic Variants With Migraine Subclassified by Clinical Symptoms in Adult Females (2021) (3)
Supplementary Material 7 (2014) (3)
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials (2023) (3)
A tale of three labels: translating the JUPITER trial data into regulatory claims (2011) (3)
Genome-wide association study of kidney function decline in individuals of European descent: the CKDGen Consortium. (2015) (3)
The genomics of heart failure: design and rationale of the HERMES consortium (2021) (3)
Response: Re: C-Reactive Protein and Risk of Breast Cancer (2008) (3)
The neutrophil-lymphocyte ratio: considerations for clinical application. (2021) (3)
307-S: Magnesium Intake, C-Reactive Protein, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older us Women (2005) (3)
Methotrexate for Prevention of Cardiovascular Events. Reply. (2019) (3)
Racial differences in coronary heart disease incidence and mortality. Methodologic mythology? (1990) (3)
Polymorphism in the 2-Adrenergic Receptor and Lipoprotein Lipase Genes as Risk Determinants for Idiopathic Venous Thromboembolism (2006) (3)
Supplementary Material 6 (2014) (3)
Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein Cholesterol) and Triglyceride Concentrations (2021) (3)
New light on secretory-component deficiency. (1992) (3)
Supplementary Material 3 (2015) (3)
Multi-ethnic genome-wide association study for atrial fibrillation (2018) (3)
Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research. (2017) (3)
and Atherosclerotic Cardiovascular Disease (2009) (3)
Tryptophanyl-tRNA synthetase gene polymorphisms and risk of incident myocardial infarction. (2005) (3)
Increased Mortality Rates in the JUPITER Trial (2012) (3)
Islet amyloid polypeptide gene variation (IAPP) and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study. (2011) (3)
Formulation of treatment recommendations for statins--reply. (2014) (3)
LIPOPROTEIN(A) AND RISK OF MYOCARDIAL INFARCTION. AUTHOR'S REPLY (1994) (3)
Women : The Reynolds Risk Score the Assessment of Global Cardiovascular Risk in Development and Validation of Improved Algorithms for Supplementary material (2007) (3)
OA02.01. Effect of macronutrient composition of weight loss diets on reduction of the inflammatory marker hsCRP (2012) (3)
Lipoprotein(a), ethnicity, and cardiovascular risk: erasing a paradox and filling a clinical gap. (2012) (3)
A polymorphism in the VKORC 1-regulator calumenin predicts higher warfarin doses in African-Americans (2010) (3)
Association Between Hemostatic Profile and Migraine (2021) (3)
ATHEROGENIC LIPOPROTEIN PARTICLE SUBCLASSES AND RESIDUAL CARDIOVASCULAR RISK: AN ANALYSIS OF THE JUPITER TRIAL (2015) (3)
Editors' Consensus Report The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease r (2009) (3)
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial – Authors' reply (2009) (3)
Plasma Concentration of Cystatin-C and Mannose Binding Protein and the Risk of Developing Peripheral Vascular Disease (2001) (2)
Novel blood pressure locus and gene discovery using GWAS and expression datasets from blood and the kidney (2017) (2)
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future (2022) (2)
D-dimer and duration of anticoagulation. (2007) (2)
University of Groningen Physical Activity Attenuates the Influence of FTO Variants on Obesity Risk (2011) (2)
Fish consumption, fish oils, and cardiovascular events: still waiting for definitive evidence. (2016) (2)
Erratum: Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation (2017) (2)
Association of Endogenous Tissue Plasminogen Activator (t-PA) with Clinical Characteristics of the Insulin Resistance Syndrome (2000) (2)
Chapter 26 – Aspirin, Other Antiplatelet Agents, and Anticoagulants (2004) (2)
Abstract 1462: Association of HDL Cholesterol and Apolipoprotein A-1 With Incident CVD Across Levels of LDL Cholesterol in 27,748 Women (2009) (2)
Genome-wide meta-analyses reveal novel loci for verbal short-term memory and learning (2022) (2)
Plasma Placental Growth Factor Concentrations Are Elevated Well in Advance of Type 2 Diabetes Mellitus Onset: Prospective Data From the WHS (2019) (2)
SAFETY PROFILE OF STATIN-TREATED PATIENTS WITH LDL-C < 30MG/DL (2012) (2)
2153The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease; a cohort study (2019) (2)
pressure progression: prospective cohort study with high normal blood pressure or blood Risk of cardiovascular events among women (2007) (2)
HDL cholesterol and residual risk of first cardiovascular events – Authors' reply (2010) (2)
Oral Infections and Cardiovascular Disease (2012) (2)
Risk Factors for Cardiovascular Disease in Women—Reply (2005) (2)
Aspirin and cardiovascular disease prevention in women: new findings from the Women's Health Study. (2005) (2)
Psoriasis and Atherosclerosis. (2018) (2)
A NOVEL BIOMARKER OF CIRCULATING GLYCOPROTEINS AND CARDIOVASCULAR AND ALL-CAUSE MORTALITY AMONG 39,521 INITIALLY HEALTHY ADULTS (2015) (2)
Abstract 16055: Lipoprotein Subclasses, Size, and Statin-Associated Incident Diabetes: An Analysis From the JUPITER Trial (2014) (2)
Should Survivors of Myocardial Infarction with Low Ejection Fraction Be Routinely Referred to Arrhythmia Specialists (1997) (2)
Abstract 12037: Alanine Aminotransferase Levels and Incident Cardiovascular Events (2014) (2)
Abstract 5005: Development and Testing of a Risk Prediction Algorithm for Incident Hypertension in Women with Currently Normal Blood Pressure (2008) (2)
The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions (2023) (2)
LACK OF ASSOCIATION BETWEEN POLYMORPHISMS IN THE SLCO1B1 GENE AND CLINICAL MYALGIA FOLLOWING ROSUVASTATIN THERAPY (2012) (2)
Triggers for Inflammation in Atherogenesis Oxidized Lipoproteins and Inflammation (2002) (2)
Thrombolytic therapy for acute myocardial infarction. Applying lessons from randomized trials to community practice. (1995) (2)
358Understanding and mitigating the risk of infection with canakinumab (2018) (2)
Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more (2022) (2)
HMG CoA reduction in patients with average cholesterol concentrations. (2011) (2)
Activated Protein C Resistance, Factor V Leiden, and Venous Thromboembolism (1999) (2)
Equipoise, Trust, and the Need for Cardiologists to Randomly Assign Patients Into Anticoagulation Trials in the Time of COVID (2020) (2)
PIA1/A2 POLYMORPHISM OF PLATELET GLYCOPROTEIN IIIA AND RISK OF CARDIOVASCULAR DISEASE. AUTHORS' REPLY (1997) (2)
O-3: Abdominal adiposity predicts endothelial dysfunction in uncomplicated obesity: An analysis of traditional and novel risk factors (2001) (2)
Plasma concentration of C-reactive protein and physical activity (2003) (2)
Clinical predictors of COVID‐19 severity and bleeding in the ACTIV‐4B COVID‐19 outpatient thrombosis prevention trial (2022) (2)
Catechol‐O‐Methyltransferase and Cardiovascular Disease: MESA (2019) (2)
The editor's roundtable: JUPITER follow-up. (2011) (2)
Multi-ancestry genome-wide gene–smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids (2019) (2)
Correction: Selectivity in Genetic Association with Sub-classified Migraine in Women (2015) (2)
Sugar-sweetened Beverage Consumption May Modify Associations between Genetic Variants in the CHREBP Locus and HDL-C and TG Concentrations. (2021) (2)
Author Correction: A guiding map for inflammation (2020) (2)
Monoclonal antibodies targeting PCSK9 and the search for prolonged duration of effect. (2016) (2)
EFFECTS OF INTERLEUKIN-1β INHIBITION WITH CANAKINUMAB ON IL-6, FIBRINOGEN, AND HSCRP: A RANDOMIZED PLACEBO CONTROLLED TRIAL (2012) (2)
Clinical trials in heart disease : a companion to Braunwald's heart disease (2004) (2)
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS (2022) (2)
Is C-Reactive Protein Specific for Vascular Disease in Women? (2002) (2)
Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility (2016) (2)
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals (2018) (1)
Venous Thromboembolism G20210A Mutation in the Prothrombin Gene and the Risk of Recurrent Venous Thromboembolism (2016) (1)
Abstract 1425: Prevention of Major Cardiovascular Events With Rosuvastatin Among Patients With Impaired Fasting Glucose: The JUPITER Trial (2009) (1)
GENETIC RISK, ADHERENCE TO A HEALTHY LIFESTYLE, AND RISK OF CORONARY ARTERY DISEASE (2017) (1)
Abstract 17823: Etiology of Gender Differences in Cardiac Troponin I Concentrations (2013) (1)
Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution (2019) (1)
Statin therapy for elevated hsCRP: what are the public health implications? (2010) (1)
Gene Variation of Endoplasmic Reticulum Aminopeptidase 1 and Risk of Incident Type 2 Diabetes Mellitus amongst 22,718 Initially Healthy Women (2018) (1)
Can fishing for new genes catch patients at risk of coronary artery disease? (2008) (1)
Abstract 20653: Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort of Women: The Women’s Health Initiative (2017) (1)
Evaluation of the causal effect of fibrinogen on incident coronary heart disease via Mendelian randomization (2018) (1)
Sugar-sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in U.S. Adults. (2022) (1)
Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. (2022) (1)
Abstract 18739: Novel Protein Glycan Derived Marker of Systemic Inflammation is Associated With Incident Cardiovascular Disease (2013) (1)
C-Reactive Protein for Primary Risk Assessment (2003) (1)
Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals (2020) (1)
Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial (2021) (1)
MEGATRIALS FOR CLINICAL DECISION MAKING. AUTHORS' REPLY (1996) (1)
Paraneoplastic cerebellar degeneration in a patient with ovarian carcinoma. (1988) (1)
Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in CANTOS. (2021) (1)
Coronary Artery Calcium Scanning Should be Used for Primary Prevention (2011) (1)
Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective Cohorts. (2022) (1)
Abstract 18502: Mass and Genetic Polymorphism of Group IIA Secretory Phospholipase A2, Rosuvastatin Therapy, and Risk of Cardiovascular Events: An Analysis From the JUPITER Trial (2015) (1)
C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention (2006) (1)
Abstract 23073: Cardiovascular Efficacy of PCSK9 Inhibition Among 1,578 Patients With Familial Hypercholesterolemia: The SPIRE Clinical Trials FH Analysis (2017) (1)
Abstract 3936: Homocysteine Concentration, 5, 10-Methylenetetrahydrofolate Reductase 677C>T Gene Polymorphism, and Intake of Folate and B-Vitamins in 24,968 Asymptomatic Women (2006) (1)
Letter by Ridker and Everett regarding article, "The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?". (2007) (1)
Abstract 15969: Cardiac Troponin I as Detected by a Novel High-Sensitivity Assay Predicts Vascular Events in the JUPITER Trial (2013) (1)
Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio (2022) (1)
Supplementary Material 9 (2013) (1)
Abstract 18720: HDL Particle Subclasses, Rosuvastatin Therapy, and Risk of Vascular Events: An Analysis From the JUPITER Trial (2015) (1)
COMT Effects on Vitamin E and Colorectal Cancer, in-vitro and in Two Randomized Trials (P15-005-19). (2019) (1)
Missing centenarians in Japan: a new ageism (2010) (1)
Direct comparison of aspirin plus hirudin aspirin plus heparin, and aspirin alone among 12,000 patients with acute myocardial infarction not receiving thrombolysis: Rationale and design of the First American Study of Infarct Survival (ASIS-1) (2005) (1)
Discovery and Refinement Supplementary (2015) (1)
Corrigendum: Rare coding variants and X-linked loci associated with age at menarche (2015) (1)
Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. (2019) (1)
Erratum: Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology (The American Journal of Human Genetics (2019) 105(1) (15–28), (S0002929719301880), (10.1016/j.ajhg.2019.05.002)) (2019) (1)
Abstract P280: Revisiting CVD Risk Prediction Using Machine Learning Approaches: A Case Study (2020) (1)
Genetics of fasting indices of glucose homeostasis using GWIS unravels tight relationships with inflammatory markers (2018) (1)
’ Consensus Report The American Journal of Cardiology and Journal of Periodontology Editors ’ Consensus : Periodontitis and Atherosclerotic Cardiovascular Disease (2009) (1)
Lifestyle InteractionWith FatMass and Obesity-Associated ( FTO ) Genotype and Risk of Obesity in Apparently Healthy U . S . Women (2011) (1)
A Cross-sectional Study of Endogenous Tissue Plasminogen Activator , Total Cholesterol , HDL Cholesterol , and Apolipoproteins A-I , AII , and B100 (2005) (1)
Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (2022) (1)
Response to Letter Regarding Article, “Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women” (2009) (1)
Haplotype Analysis of the Beta-2 Adrenergic Receptor Gene and Risk of Myocardial Infarction (2004) (1)
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis (2022) (1)
THE NEUTROPHIL-LYMPHOCYTE RATIO AND SUBCLINICAL CORONARY ARTERY DISEASE: ANALYSIS FROM AN OBSERVATIONAL COHORT STUDY IN PSORIASIS (2020) (1)
Abstract 13479: Association of Plasma Branched Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women (2020) (1)
Abstract 16242: Anti-Inflammatory Therapy With Canakinumab and Reduction in Total Cardiovascular Events (2018) (1)
Ventricular Arrhythmias inTrials ofThrombolytic Therapy for AcuteMyocardial Infarction AMeta-Analysis (1993) (1)
Abstract 3160: Inflammation and Risk of Incident Atrial Fibrillation in Women (2008) (1)
IMPACT OF SEPSIS ON POSTOPERATIVE RISK OF ARTERIAL AND VENOUS THROMBOSIS (2014) (1)
Null Results in Brief Hemoglobin A 1 c Concentrations and Risk of Colorectal Cancer in Women (2005) (1)
Endogenous tissue-type plasminogen activator and myocardial infarction (1993) (1)
The relationship between severity of peripheral arterial disease and markers of inflammation (2003) (1)
Loci influencing blood pressure identified using a cardiovascular gene-centric array (Correction to Ganesh et al. 22 (8): 1663) (2013) (1)
Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles (2022) (1)
Supplementary Material 4 (2015) (1)
Reduction in C-Reactive Protein and Low-Density Lipoprotein Cholesterol and Cardiovascular Event Rates After Initiation of Rosuvastatin: A Prospective Study of the justification for the Use of Statins in Prevention: An Intervention, Trial Evaluating Rosuvastatin Trial (2009) (1)
Tracking of High-Sensitivity C-Reactive Protein after Observation of an Initially Increased Concentration: The JUPITER Study (2008) (1)
Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity (2019) (1)
Human Papillomavirus Infection: An Inflammatory Trigger for Atherosclerosis? (2019) (1)
87. The Physicians' Health Study: prospective evaluations of tPA and PAI-1 (1996) (1)
Association between polymorphisms in the β2-adrenergic receptor gene with myocardial infarction and ischemic stroke in women (2009) (1)
Polygenic overlap between C-reactive protein , plasma lipids and Alzheimer ’ s disease 1 2 (2017) (1)
Comparison of Lifestyle Based to Traditional CVD Prediction in a Multiethnic Cohort of Non-Smoking Women (2014) (1)
Blood pressure and risk of developing type 2 diabetes mellitus : The Women's Health Study. Commentary (2007) (1)
Abstract 2184: Prospective Evaluation of a Comprehensive Genetic Risk Score for Future Cardiovascular Events Among 19,313 Initially Healthy Women: The Women's Genome Health Study (2009) (1)
Pharmacogenetic study of statin therapy and cholesterol reduction. (2004) (1)
HOMOCYSTEINE IS ASSOCIATED WITH FUTURE VENOUS THROMBOEMBOLISM IN TWO PROSPECTIVE COHORTS OF WOMEN (2018) (1)
Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Men and Women with Elevated Levels of C-Reactive Protein: The JUPITER Trial (2008) (1)
Coronary artery calcium for guiding statin treatment (2012) (1)
Supplementary Material 15 (2013) (1)
Prediction of 10-year and lifetime risk of cancer in individual patients with established cardiovascular disease, results from UCC-SMART and CANTOS (2020) (1)
Time to presentation for acute mi in the us physicians' health study (1990) (1)
HYPERTRIGLYCERIDEMIA, INFLAMMATION, HYPERCHOLESTEROLEMIA, AND FUTURE CARDIOMETABOLIC DISEASE RISK: A DATA DRIVEN CLUSTER ANALYSIS IN THE WOMEN's HEALTH STUDY (2020) (0)
Means for determining a person's risk for atherosclerotic disease (1998) (0)
Abstract 9522: Hs-CRP, Statin Therapy, and Risks of Atrial Fibrillation: An Exploratory Analysis of the JUPITER Trial (2011) (0)
PI A1/A2 polymorphism of platelet glycoprotein Illa and risk of cardiovascular disease (1997) (0)
Lack of association between genetic variation in 9 innate immunity genes and baseline CRP levels. (2006) (0)
Publisher Correction: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes (2019) (0)
JUPITER Study Continues to Make News (2009) (0)
Abstract MP01: Physical Activity and Incident Cardiovascular Disease in Women: Is the Relation Influenced by Level of Global Cardiovascular Risk? (2015) (0)
Candidate loci shared among periodontal disease, diabetes and bone density (2023) (0)
Abstract B79: Novel protein glycan biomarker and future colorectal cancer (2016) (0)
Prospective Genetic Analysis Population-Based , Determinants for Idiopathic Venous Thromboembolism : A Multilocus ,-Adrenergic Receptor and Lipoprotein Lipase Genes as Risk 2 β Polymorphism in the Print (2006) (0)
Canakinumab Effects on Erythropoiesis, Cardiovascular Risk, and Clonal Hematopoiesis: Proteogenomic Analysis of the Cantos Randomized Clinical Trial (2022) (0)
Soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) correlates with carotid thickness (1998) (0)
Abstract 3113: Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women's Health Study (2007) (0)
Current and future perspectives on antithrombic therapy of acute myocardial infarction (1995) (0)
Coronary Flow Reserve, Inflammation and Myocardial Strain in the Cardiovascular Inflammation Reduction Trial (CIRT-CFR) (2022) (0)
C-reactive protein and electron beam computed tomography: a perfect match?: reply (2001) (0)
A prospective study of hemoglobin A1c and future cardiovascular events in women (2003) (0)
Moving Beyond TNF : New Targets of Therapy Infl ammation in Cardiovascular Disease : Links to Rheumatoid Arthritis IL-6 Receptor Inhibition (2009) (0)
Book Review Prognosis and Risk Assessment in Cardiovascular Disease Edited by Amar S. Kapoor and Bramah N. Singh. 578 pp., illustrated. New York, Churchill Livingstone, 1993. $79.95. 0-443-08768-7 (1993) (0)
Thrombosis and Thromboembolism: New Strategies for Improved Patient Care (1998) (0)
Abstract 2185: The Relative Strength of C-Reactive Protein and Lipid Levels as Predictors of Ischemic Stroke as Compared to Coronary Heart Disease (2006) (0)
Relationship of Obesity with C-Reactive Protein and Interleukin-6 in Women (2001) (0)
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein Clinical Investigation and Reports (1999) (0)
Induction of fc receptor-bearing cells with anti-ig. Abstr. (1981) (0)
The genetic basis of cross-phenotype correlation with bone fracture risk: the GEFOS consortium (2013) (0)
Abstract 16860: Warfarin Dosing in Patients with the CYP2C9*5 Variant (2010) (0)
Lipoprotein(a) Concentration and Risk of Atherothrombotic Disease-Reply (1995) (0)
allele in the 330 Japanese people in our study suggests that this allele does not have an important role in the risk of cardiovascular events in Japan. (1997) (0)
Abstract 033: Directly Measured Triglyceride-Rich Lipoprotein Cholesterol and Small Dense LDL-Cholesterol Concentrations Associate With Incident Cardiovascular Disease: Prospective Data From the Women’s Health Study (2019) (0)
Inflammation in Systemic Vascular Disease: What Can We Learn? (2006) (0)
BASIC AND TRANSLATIONAL—BILIARY Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies (2016) (0)
Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease (2018) (0)
allele in the 330 Japanese people in our study suggests that this allele does not have an important role in the risk of cardiovascular events in Japan. (1997) (0)
Abstract 2182: Physical Activity Modifies the Effect of CETP Polymorphism on HDL-C Levels in 21,705 Women of European Ancestry (2009) (0)
P Peripheral Vascular Disease Elevated Levels of Inflammation , D-Dimer , and Homocysteine Are Associated With Adverse Calf Muscle Characteristics and Reduced Calf Strength in Peripheral Arterial Disease (2007) (0)
Author Response (2011) (0)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (0)
13-OR: Effects of Randomized Statin Therapy vs. Placebo on Plasma Branched-Chain Amino Acids (BCAAs) and Type 2 Diabetes (T2D) Risk: Secondary Analysis of the JUPITER Trial (2021) (0)
424-S: Association of Dietary Glycemic Load and Dietary Glycemic Index with Plasma High Density Lipoprotein Cholesterol and Triglyceride Levels in a Large Cohort of Middle-Aged Women (2005) (0)
Abstract 13310: Anti-Inflammatory HDL Function and Incident Cardiovascular/Death Events: A Secondary Analysis of the JUPITER Trial (2018) (0)
Supplementary Material (nature09270-s1) (2012) (0)
Biomarkers for prediction of cardiovascular events. (2007) (0)
Genetic analysis of endometriosis and depression identifies shared loci and implicates causal links with gastric mucosa abnormality (2020) (0)
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? Authors' reply (2003) (0)
Abstract 2178: Does Lifestyle Modify the Genetic Risk of Obesity? An Association Study of Lifestyle Interactions With FTO Genotype in 21,675 Caucasian Women (2009) (0)
A catalog of genetic loci associated with kidney function from analyses of a million individuals (2019) (0)
The association between inflammatory markers and thrombogenic factors in postinfarction patients (2002) (0)
Response to letter regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy". (2014) (0)
Abstract P346: Novel Protein Glycan Derived Marker of Systemic Inflammation is Associated with Incident Coronary Heart Disease and Ischemic Stroke (2014) (0)
Reproductive aging-associated common genetic variants and the risk of breast cancer (2012) (0)
CHOLESTEROL EFFLUX CAPACITY, HDL-PARTICLE NUMBER, AND INCIDENT CARDIOVASCULAR EVENTS: RESULTS FROM THE JUPITER TRIAL (2016) (0)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2018) (0)
Abstract P260: Determinants of Statin Response: A Secondary Analysis of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) (2020) (0)
Low dose. (2005) (0)
C-Reactive Protein and Prediction of Vascular Events: Is There Really a Controversy? (2004) (0)
Effect of pravastatin on low-density lipoprotein particle concentration as determined by nuclear magnetic resonance spectroscopy: Results from the pravastatin inflammation/CRP evaluation (PRINCE) trial (2003) (0)
Risk factors for cardiovascular disease in women. Authors' reply (2005) (0)
Inflammation and Atherothrombosis: Where Have We Been? Where Are We Going? Why Perform the CIRT and CANTOS Trials? From Bench to Bedside to Population and Back: A Story of Clinical Translation (2013) (0)
tient enrollment on the basis of nonfasting triglyceride lev- els or after a standardized OTTT. (2017) (0)
Abstract 21094: Evaluation of Inflammatory and Thrombotic Candidate Genes with Incident Diabetes in Women (2010) (0)
Abstract 13397: Determining the Optimal Cutpoint Value for the Diagnosis of Hypertriglyceridemia in the Nonfasting Population (2014) (0)
Publisher Correction: Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits (2018) (0)
C-reactive protein as a potential therapeutic target in patients with coronary artery disease (2005) (0)
Bringing JUPITER down to earth (2009) (0)
Alcohol Consumption and Tissue-Type Plasminogen Activator-Reply (1995) (0)
Correction to: Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study (2018) (0)
Meta-analyzed single SNP interactions with physical activity* on BMI. (2013) (0)
Elevated plasma homocysteine was associated with increased mortality. (1998) (0)
Concise report Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial Rheumatology (2021) (0)
Risk of type 2 diabetes mellitus in those with hypertension: reply (2008) (0)
Abstract 3982: Lipoprotein(a), Hormone Replacement Therapy and the Risk of Future Cardiovascular Disease in Women (2006) (0)
Whole-genome sequencing and deep imputation identifies non-coding variants near Engrailed-1 with large effects on bone mineral density and fracture (2015) (0)
696 Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double blind, placebo-controlled trial (2022) (0)
Some herbal teas can be toxic. (1989) (0)
Publisher Correction: Identification of 371 genetic variants for age at first sex and birth linked to externalising behavior (2021) (0)
Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study (2017) (0)
Dietary glycemic index, dietary glycemic load, blood lipids, and C-reactive protein share how this access benefits you. Your story matters (2008) (0)
Mediterranean Diet And Reduced Risk Of Diabetes: Potential Mediating Mechanisms (2019) (0)
OP-EHEA180714 3987..3998 (2018) (0)
Abstract 5790: High Levels of Homocysteine and D-dimer Are Associated With Faster Functional Decline Among Men and Women With Lower Extremity Peripheral Arterial Disease (2009) (0)
Use of an agent to decrease the risk of cardiovascular disease. (1998) (0)
Relationship between serum amyloid A and coronary artery disease in women: The NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study (2003) (0)
Abstract 1093: A Prospective Comparison of NMR-Measured Large Versus Small LDL particles with Incident CHD in 27,673 Initially Healthy Women (2007) (0)
Abstract P330: Effect of Randomized Omega-3 Treatment on Downstream Bioactive Lipids and Their Association With Incident Cardiovascular Disease Events: Metabolomic Studies of the Vital and Jupiter Trials (2023) (0)
Abstract 04: Fried Food Consumption and Genetic Predisposition to Obesity (2014) (0)
Burden : Writing Group III High-Risk Patient for Primary Prevention : Noninvasive Tests of Atherosclerotic Prevention Conference V : Beyond Secondary Prevention : Identifying the (2008) (0)
Abstract 9724: Impaired Renal Function is Associated with an Increased Risk for Incident Atrial Fibrillation (2011) (0)
A genome-wide analysis of 'Bounty' descendants implicates several novel variants in migraine susceptibility (2012) (0)
901-79 Borderline Isolated Systolic Hypertension and Subsequent Risk of Cardiovascular Disease (1995) (0)
Abstract 6207: Derivation of a Novel Prediction Algorithm for Idiopathic Venous Thromboembolism in Women (2008) (0)
Inflammation is not associated with coronary microvascular dysfunction in women with chest pain (2003) (0)
Abstract 40: Score Based on Immunoglobulin G N-glycans for Cardiovascular Risk Prediction: Secondary Analysis of Two Randomized Trials of Primary and Secondary Prevention (2023) (0)
Unraveling Vascular Inflammation (0)
ASSOCIATION OF BASELINE MODEST ALCOHOL CONSUMPTION AND CORONARY MICROVASCULAR DYSFUNCTION IN THE CARDIOVASCULAR INFLAMMATION REDUCTION TRIAL (CIRT-CFR) (2023) (0)
C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations (2023) (0)
Abstract 3787: Nontraditional Risk Factors and Cardiovascular Disease Incidence in Type 2 Diabetes: Prospective Data from the Women's Health Study (2007) (0)
Abstract 4023: Do Known Risk Factors Explain the Inverse Relation Between Physical Activity and Cardiovascular Disease Risk? (2006) (0)
Prospective Evaluation of the Alcohol Dehydrogenase (cid:1) 1/ (cid:1) 2 Gene Polymorphism and Risk of Stroke (2004) (0)
EFFICACY OF ROSUVASTATIN AMONG MEN AND WOMEN WITH CHRONIC KIDNEY DISEASE AND ELEVATED HSCRP: THE JUPITER TRIAL (2010) (0)
Abstract 3124: The Magnitude of Reclassification Indices for Individual Predictors of Global Cardiovascular Risk (2008) (0)
Background—It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether (2013) (0)
, 2016 Evidence for CRP : Strong Positive Associations With Atherothrombotic Disease in Primary and Secondary Prevention , Neutral Data for Causality (0)
Abstract 19867: Fasting Ghrelin, Body Mass Index and Risk of Incident Diabetes in Women (2010) (0)
Abstract 14380: The Effect of Canakinumab on the Rates of Non-ST-Segment Elevation and ST-Segment Elevation Myocardial Infarctions (2018) (0)
Chapter 11 – Statins, Inflammation, and C-Reactive Protein (2004) (0)
Genome-wide association and functional follow-up reveals new loci for kidney function | NOVA. The University of Newcastle's Digital Repository (2012) (0)
Abstract 12536: A Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women with and without Diabetes: The Women's Health Study (2010) (0)
Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells (2019) (0)
EFFICACY OF ROSUVASTATIN IN PRIMARY PREVENTION ACCORDING TO BASELINE LEVELS OF HSCRP IN THE JUPITER TRIAL (2010) (0)
Abstract: 1071 PLASMA PENTRAXIN 3 LEVELS REFLECT METABOLIC SYNDROME IN PATIENTS WITH CORONARY ARTERY DISEASE (2009) (0)
Low-Dose Aspirin Therapy for Chronic Stable Angina (2020) (0)
Abstract 2733: A Common Kinesin Family Member 6 (KIF6) Variant is Associated with Coronary Heart Disease in the Women's Health Study (2007) (0)
Lipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials (2019) (0)
C-reactive protein and risk for colorectal cancer. Authors' reply (2005) (0)
Abstract 12158: Impact of Modifiable Risk Factors on Circulating Concentrations of B-type Natriuretic Peptide and Cardiac Troponin T (2015) (0)
Obesity and Risk of Death (2009) (0)
Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. (2023) (0)
Abstract 5000: A Prospective Examination of the Association of Nuclear Magnetic Resonance Measured Lipoprotein Particles with Incident Hypertension in the Women's Health Study (2008) (0)
Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults (2022) (0)
Abstract 630: Lipoprotein Subclasses by Ion Mobility and First Cardiovascular Events: An Analysis of 11,227 Participants From the JUPITER Trial (2014) (0)
Abstract 904: A Comparative Genomics Approach Identifies A Polymorphism In Calumenin As A Predictor Of High Warfarin Dose In African American Patients. (2007) (0)
Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes (2018) (0)
Abstract 140: Plasma Interleukin-6 Levels And Cardiovascular Events In The Cirt Trial: Consistent Associations For Incident Coronary, Cerebrovascular, And Peripheral Artery Disease (2022) (0)
Routine vs Selective Invasive Strategies in Acute Coronary Syndromes (2016) (0)
Abstract 3612: Lipoprotein(a), Factor V Leiden Mutation and the Risk of Future Venous Thromboembolism in Women (2007) (0)
Abstract 3073: Metabolic Syndrome, Inflammation and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study (2008) (0)
as Predictors of Sudden Cardiac Death Prospective Study of C-Reactive Protein , Homocysteine , and Plasma Lipid Levels (2002) (0)
Reply: Inflammatory Pathways in CVD and Diabetes: Broad-Spectrum Versus Selective Targeting. (2018) (0)
Correction to: Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study (2018) (0)
Rosuvastatin Reduces Primary Cardiovascular Events in Apparently Healthy Individuals with Elevated C-Reactive Protein Levels (2009) (0)
POS0219 EFFECT OF LOW-DOSE METHOTREXATE ON ESTIMATED GLOMERULAR FILTRATION RATE AND KIDNEY ADVERSE EVENTS IN THE CARDIOVASCULAR INFLAMMATION REDUCTION TRIAL (2021) (0)
Triggers for Inflammation in Atherogenesis Oxidized Lipoproteins (2002) (0)
Circulating blood markers and calf muscle characteristics in peripheral arterial disease (2007) (0)
Preventive cardiology abstractsProjected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels☆ (2002) (0)
Megatrials for Clinical Decision Making (1996) (0)
Abstract A08: Lipid biomarkers and cancer risk: Long-term observational follow-up of cancer in the Women's Health Study (2015) (0)
858-4 C-reactive protein levels and race/ethnicity (2004) (0)
KIF6 POLYMORPHISM AND THE EFFICACY OF STATIN THERAPY IN PRIMARY PREVENTION: DATA FROM THE JUPITER TRIAL (2011) (0)
A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine (2020) (0)
Abstract 3503: Low Dose Aspirin and Incident Diabetes Mellitus in Apparently Healthy Middle-Aged American Women - the Women's Health Study (2007) (0)
THE NEUTROPHIL-LYMPHOCYTE RATIO AND ATHEROSCLEROTIC EVENTS: ANALYSES FROM FIVE CONTEMPORARY RANDOMIZED CONTROLLED TRIALS (2020) (0)
Means for evaluating the risk profile of an individual suffering an atherosclerotic disease. (1998) (0)
Anti-Inflammatory Mechanisms in the Vascular Wall Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque Novel Clinical Markers of Vascular Wall Inflammation CD40 Signaling and Plaque Instability Innate and Adaptive Immune Mechanisms in Atherosclerosis (2001) (0)
Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial. (2021) (0)
Abstract 10633: The Complete Blood Count Risk Score and Its Components Including the Red Cell Distribution Width are Associated With Mortality in the JUPITER Trial (2013) (0)
ALCOHOL CONSUMPTION AND TISSUE-TYPE PLASMINOGEN ACTIVATOR. AUTHORS' REPLY (1995) (0)
Abstract 12260: Sex Differences in Cardiac Troponin I and the Risk of Death or Major Cardiovascular Events in Primary Prevention (2015) (0)
Meta-analysis of LDL-C Lowering and Mortality. (2018) (0)
Use of an agent for reducing the risk of cardiovascular diseases (1998) (0)
Aspirin and Cardiovascular Disease Prevention in Women: New Findings from the Women's Health Study (2005) (0)
NT-PROBNP AND THE RISK OF INCIDENT DIABETES IN WOMEN (2011) (0)
Inflammation and Atherosclerosis Clinical Cardiology: New Frontiers (2002) (0)
Conundrum Inflammatory Biomarkers, Statins, and the Risk of Stroke: Cracking a Clinical (2010) (0)
Canakinumab's Effect Against Subsequent Gout Flares and High‐Sensitivity C‐Reactive Protein Levels: A Causal Mediation Analysis (2023) (0)
Biomarkers of Inﬂammation and Thrombosis as Predictors of Near-Term Mortality in Patients with Peripheral Arterial Disease: A Cohort Study (2007) (0)
Biological basis and proposed mechanism of action of CSL112 (Apolipoprotein A-I [Human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction. (2021) (0)
Abstract 1426: Rosuvastatin for the Primary Prevention of Cardiovascular Events in Women With Elevated hsCRP and Low LDLC: Sex-Specific Outcomes From the JUPITER Trial (2009) (0)
Cholesteryl Ester Transfer Protein (CETP) Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events (2013) (0)
Molecular genetic overlap between migraine and major depressive disorder (2018) (0)
Pharmacogentic factors affecting INR control during warfarin initiation (2008) (0)
Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity (2019) (0)
Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease. (2022) (0)
The first experience of information pharmacogenetic testing to predict the dose of warfarin (2011) (0)
Abstract 4987: A Formal Comparison of Risk Factors for Coronary Versus Lower Extremity Peripheral Arterial Disease - Are the Risk Factors Truly the Same? (2008) (0)
Abstract 5600: Genetic variants associated with reproductive aging and the risk of breast cancer (2011) (0)
Outpatient Randomized Controlled Trials in the Covid-19 Era and Beyond (2022) (0)
Abstract: 90 PRIMARY PREVENTION OF HEART DISEASE (2009) (0)
Abstract 16387: The Contribution of Novel Genetic Markers to Atrial Fibrillation Risk Prediction Models (2010) (0)
C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events An 8-Year Follow-Up of 14 719 Initially Healthy American Women Clinical Investigation and Reports (2003) (0)
INFLAMMATION AND NEUROLOGICAL DISEASE (2005) (0)
Genome-Wide Association Study Evaluating Lp-PLA 2 Mass and Activity at Baseline and Following Rosuvastatin Therapy Running title : (2012) (0)
C-Reactive Protein -- Inflammatory Marker and More in Cardiovascular Disease: An Expert Interview With Paul M. Ridker, MD, MPH, FACC, (2005) (0)
P5328Clinical and demographic predictors of attenuated LDL-C response to PCSK9 inhibition with bococizumab: Insights from the SPIRE trials (2019) (0)
Coronary Artery Calcium Scanning and Conflicts of Interest—Reply (2012) (0)
Title Page / Table of Contents, Vol. 27, Suppl. 1, 1997 (1997) (0)
Autoimmune diseases and atherothrombotic risk (2022) (0)
Genome-Wide Association Study for Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort Studies : The CHARGE Consortium Dehghan (2016) (0)
P619Incident premature coronary heart disease in women: an analysis of 53 biomarkers from the Women's Health Study (2018) (0)
Genetic Testing: Moving to the Bedside—When and How? (2009) (0)
Contents Vol. 120, 2011 (2012) (0)
C-Reactive Protein and Risk for Colorectal Cancer (2005) (0)
Cost-effectiveness of C-reactive protein screening to target statin therapy (2002) (0)
Relevance of achieved levels of systemic inflammation markers after treatment (2005) (0)
Inflammation and risk of recurrent cardiovascular events according to prior vascular disease location (2022) (0)
Abstract 9898: Weight Loss Decreases High Sensitivity C-Reactive Protein Irrespective of Dietary Composition (2011) (0)
A network of pleiotropic genes for metabolic syndrome and inflammation (2013) (0)
Abstract 5092: Association of Genetic Variation of Factor VII, Interleukin-1 beta, and Interleukin-10 with Risk of Incident Idiopathic Venous Thromboembolism in 22,407 Initially Healthy White Women (2008) (0)
Abstract 19462: Improvement of 10-Year Cardiovascular Risk Prediction Using Hemoglobin A1c in Diabetic Women Compared to Classification of Diabetes as a Cardiovascular Risk Equivalent (2010) (0)
University of Groningen Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci Tragante, (2014) (0)
Vascular medicine--a scientific profile. (2001) (0)
Abstract 16968: A Randomized Trial of the Effects of Insulin and Metformin on Myocardial Stress in Patients With Type II Diabetes Mellitus (2017) (0)
Patients Based on Individualized Prediction of Treatment Effect High-Dose Statin Therapy in Patients with Stable Coronary Artery Disease: Treating the Right (2013) (0)
Justification for the Use of Statin in Prevention : An Intervention Trial Evaluating Rosuvastatin ( JUPITER ) : Rationale and Prespecified Analyses (2009) (0)
Abstract 3613: Lipid Biomarkers, Hormone Therapy, and the Risk of Unprovoked Venous Thromboembolism in Women (2007) (0)
Abstract 10607: Effects of Low-Dose Methotrexate on Brachial Artery Echogenicity and Grayscale Texture in HIV-Infected Individuals at Increased Cardiovascular Disease Risk: AIDS Clinical Trials Group Study A5314 (2018) (0)
Review Are statins anti-inflammatory? (2000) (0)
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure (2020) (0)
Algorithms for assessing cardiovascular risk in women. Authors' reply (2007) (0)
Dr. Moyad’s Expert Interview: Paul M. Ridker, MD (2005) (0)
Analysis of potential protein-modifying variants in 9000 endometriosis patients and 150000 controls of European ancestry (2017) (0)
Author Correction: Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis (2022) (0)
Publisher Correction: Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals (2021) (0)
THROMBOSIS AND HEMOSTASIS Rare and low-frequency variants and their association with plasma levels of ﬁ brinogen, FVII, FVIII, and vWF (2015) (0)
LEISURE-TIME PHYSICAL ACTIVITY ASSOCIATES FAVORABLY WITH THE BIOACTIVE LIPIDOME AND RISK OF INCIDENT CVD EVENTS/ RESULTS FROM THE VITAMIN D AND OMEGA-3 TRIAL (VITAL) AND JUPITER TRIALS (2021) (0)
Algorithms for Assessing Cardiovascular Risk in Women—Reply (2007) (0)
C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation. Authors' reply (2003) (0)
Abstract 10030: Validation of Framingham and Reynolds Cardiovascular Risk Prediction Models in the Women's Health Initiative (2011) (0)
W26 DISCORDANCE BETWEEN LDL CHOLESTEROL AND LDL PARTICLE CONCENTRATION IN RELATION TO INCIDENT CVD EVENTS IN 27673 WOMEN (2010) (0)
Are Statins Anti-Inflammatory? The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (0)
Nonfasting Triglycerides and Cardiovascular Risk—Reply (2007) (0)
Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1 (2022) (0)
Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop (2022) (0)
PROGNOSTIC VALUE OF SERIAL C-REACTIVE PROTEIN LEVELS AFTER AN ACUTE CORONARY SYNDROME: AN ANALYSIS FROM PROVE-IT TIMI 22 (2012) (0)
Multiethnic Cohort of Nonsmoking Women Comparison of Lifestyle-Based and Traditional Cardiovascular Disease Prediction in a (2014) (0)
Abstract 12828: Mediterranean Diet and Reduced Risk of Cardiovascular Disease: Potential Mediating Mechanisms (2018) (0)
Response to S. Verma and E. T. H. Yeh: C-reactive protein and atherothrombosis—Beyond a biomarker: an actual partaker of lesion formation (2003) (0)
Are Statins Anti-Inflammatory? The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (0)
Gly is associated blunted creatine kinase variation , but not with myalgia Running title : CKM Glu 83 Gly , creatine kinase and myalgia (2017) (0)
Abstract 16061: Lipoprotein(a) and Cardiovascular Risk Prediction in Women (2017) (0)
of Ischemic Stroke Compared With Coronary Heart Disease in Women The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants (2010) (0)
Cardiovascular Disease Part 3 : New Developments in Evaluating the Role of CRP as a Marker for Cardiovascular Disease (2004) (0)
Elevated plasma homocysteine was associated with increased risk of vascular disease. (1998) (0)
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits (2018) (0)
Abstract 16278: Discordant Lipid Phenotype and Other Determinants of Statin Response in the Pravastatin Inflammation/crp Evaluation (PRINCE) Trial (2020) (0)
Genetic Risk Score and Cardiovascular Events in Women—Reply (2010) (0)
Lipoprotein(a) and Risk of Myocardial Infarction-Reply (1994) (0)
Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function: Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II (1993) (0)
GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes (2018) (0)
Advances in modeling of the bovine estrous cycle: Synchronization with PGF2 (2022) (0)
RESIDUAL RISK AND ON-STATIN REDUCTIONS IN TRIGLYCERIDES, REMNANT CHOLESTEROL, AND VLDL LIPOPROTEINS: AN ANALYSIS FROM THE JUPITER TRIAL (2016) (0)
Functional characterization of GWAS loci associated with fracture risk (2013) (0)
Abstract 13007: LDL-Triglyceride Content, LDL-Cholesterol to LDL-Triglyceride Ratio,and Associations With Incident Cardiovascular Disease: Prospective Data From the Women’s Health Study (2019) (0)
Abstract 1574: Individual and Joint Effects of Metabolic Syndrome Components and Risk of Incident Atrial Fibrillation in Women (2009) (0)
Association of Genetic Variants with the Metabolic Syndrome in 20,806 Caucasian Women: The Women's Health Genome Study (2009) (0)
Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. (2021) (0)
Abstract: S6-27 USING NOVEL RISK FACTORS IN CLINICAL TRIALS (2009) (0)
Readers' commentAuthor's Reply (2011) (0)
Response to Letter Regarding Article, “Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women’s Health Study” (2008) (0)
Abstract 884: Effects of a Low-Fat Diet and Nutritional Supplements on Inflammatory Markers of Atherosclerosis in Hyperlipidemic Children: The EARLY Trial (2009) (0)
Coronary Flow Reserve, Inflammation, and Myocardial Strain (2022) (0)
n g l a d r n a l of m e d i c i n e Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (2017) (0)
Abstract 18416: Discordance Between nonHDLc and Lipoprotein Particle Concentration (apoB and LDLp) in Relation to Future Coronary Events in Women (2015) (0)
Genome-wide analysis of dental caries and periodontitis combining clinical and self-reported data (2019) (0)
OP0014 Serum urate, gout, and cardiovascular disease in a randomised controlled trial of canakinumab: a cantos secondary analysis (2018) (0)
The effect of ziltivekimab on the neutrophil-lymphocyte ratio: analysis from RESCUE (2022) (0)
A Novel Approach to Medical Monitoring During the SARS-CoV-2 Pandemic Supporting the ACTIV 4B Outpatient Anticoagulation Trial (2021) (0)

This paper list is powered by the following services:

Other Resources About Paul Ridker

en.wikipedia.org

What Schools Are Affiliated With Paul Ridker?

Paul Ridker is affiliated with the following schools: